317 results on '"Floridia, M."'
Search Results
2. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
- Author
-
Agweng, E, Awio, P, Bakeinyaga, G, Isabirye, C, Kabuga, U, Kasuswa, S, Katuramu, M, Kiweewa, F, Kyomugisha, H, Lutalo, E, Mulima, D, Musana, H, Musitwa, G, Musiime, V, Ndigendawan, M, Namata, H, Nkalubo, J, Labejja, P Ocitti, Okello, P, Olal, P, Pimundu, G, Segonga, P, Ssali, F, Tamale, Z, Tumukunde, D, Namala, W, Byaruhanga, R, Kayiwa, J, Tukamushaba, J, Abunyang, S, Eram, D, Denis, O, Lwalanda, R, Mugarura, L, Namusanje, J, Nankya, I, Ndashimye, E, Nabulime, E, Senfuma, O, Bihabwa, G, Buluma, E, Elbireer, A, Kamya, D, Katwere, M, Kiggundu, R, Komujuni, C, Laker, E, Lubwama, E, Mambule, I, Matovu, J, Nakajubi, A, Nakku, J, Nalumenya, R, Namuyimbwa, L, Semitala, F, Wandera, B, Wanyama, J, Mugerwa, H, Ninsiima, E, Ssenkindu, T, Mwebe, S, Atwine, L, William, H, Katemba, C, Acaku, M, Ssebutinde, P, Kitizo, H, Kukundakwe, J, Naluguza, M, Ssegawa, K, Namayanja, Nsibuka, F, Tuhirirwe, P, Fortunate, M, Acen, J, Achidri, J, Amone, A, Chamai, M, Ditai, J, Kemigisa, M, Kiconco, M, Matama, C, Mbanza, D, Nambaziira, F, Odoi, M Owor, Rweyora, A, Tumwebaze, G, Kalanzi, H, Katabaazi, J, Kiyingi, A, Mbidde, M, Mugenyi, M, Okong, P, Senoga, I, Abwola, M, Baliruno, D, Bwomezi, J, Kasede, A, Mudoola, M, Namisi, R, Ssennono, F, Tuhirwe, S, Amone, G, Abach, J, Aciro, I, Arach, B, Kidega, P, Omongin, J, Ocung, E, Odong, W, Philliam, A, Alima, H, Ahimbisibwe, B, Atuhaire, E, Atukunda, F, Bekusike, G, Bulegyeya, A, Kahatano, D, Kamukama, S, Kyoshabire, J, Nassali, A, Mbonye, A, Naturinda, T M, Ndukukire, Nshabohurira, A, Ntawiha, H, Rogers, A, Tibyasa, M, Kiirya, S, Atwongyeire, D, Nankya, A, Draleku, C, Nakiboneka, D, Odoch, D, Lakidi, L, Ruganda, R, Abiriga, R, Mulindwa, M, Balmoi, F, Kafuma, S, Moriku, E, Reid, A, Chidziva, E, Musoro, G, Warambwa, C, Tinago, G, Mutsai, S, Phiri, M, Mudzingwa, S, Bafana, T, Masore, V, Moyo, C, Nhema, R, Chitongo, S, Heyderman, Robert, Kabanga, Lucky, Kaunda, Symon, Kudzala, Aubrey, Lifa, Linly, Mallewa, Jane, Moore, Mike, Mtali, Chrissie, Musowa, George, Mwimaniwa, Grace, Sikwese, Rosemary, Ziwoya, Milton, Chitete, H Chimbaka B, Kamanga, S, Makwakwa, T Kayinga E, Mbiya, R, Mlenga, M, Mphande, T, Mtika, C, Mushani, G, Ndhlovu, O, Ngonga, M, Nkhana, I, Nyirenda, R, Cheruiyot, P, Kwobah, C, Ekiru, W Lokitala, Mokaya, M, Mudogo, A, Nzioka, A, Tanui, M, Wachira, S, Wools-Kaloustian, K, Alipalli, P, Chikatula, E, Kipaila, J, Kunda, I, Lakhi, S, Malama, J, Mufwambi, W, Mulenga, L, Mwaba, P, Mwamba, E, Namfukwe, M, Kerukadho, E, Ngwatu, B, Birungi, J, Boles, J, Burke, A, Castle, L, Ghuman, S, Kendall, L, Tebbs, S, Whittle, J, Wilkes, H, Young, N, Spyer, M, Kapuya, C, Kyomuhendo, F, Kyakundi, D, Mkandawire, N, Mulambo, S, Senyonjo, S, Angus, B, Arenas-Pinto, A, Palfreeman, A, Post, F, Ishola, D, Arribas, J, Colebunders, R, Floridia, M, Giuliano, M, Mallon, P, Walsh, P, De Rosa, M, Rinaldi, E, Weller, I, Gilks, C, Kangewende, A, Luyirika, E, Miiro, F, Ojoo, S, Phiri, S, Wapakabulo, A, Peto, T, Matenga, J, Cloherty, G, van Wyk, J, Norton, M, Lehrman, S, Lamba, P, Malik, K, Rooney, J, Snowden, W, Villacian, J, Hakim, James G, Thompson, Jennifer, Kityo, Cissy, Hoppe, Anne, Kambugu, Andrew, van Oosterhout, Joep J, Lugemwa, Abbas, Siika, Abraham, Mwebaze, Raymond, Mweemba, Aggrey, Abongomera, George, Thomason, Margaret J, Easterbrook, Philippa, Mugyenyi, Peter, Walker, A Sarah, and Paton, Nicholas I
- Published
- 2018
- Full Text
- View/download PDF
3. Diagnosis of HIV Infection in Pregnancy: Data from a National Cohort of Pregnant Women with HIV in Italy
- Author
-
Floridia, M., Ravizza, M., Tamburrini, E., Anzidei, G., Tibaldi, C., MacCabruni, A., Guaraldi, G., Alberico, S., Vimercati, A., Antoni, A. Degli, and Ferrazzi, E.
- Published
- 2006
4. Pregnant with HIV before age 25 : data from a large national study in Italy, 2001–2016
- Author
-
The Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy, FLORIDIA, M., MASUELLI, G., TAMBURRINI, E., CETIN, I., LIUZZI, G., MARTINELLI, P., GUARALDI, G., SPINILLO, A., VIMERCATI, A., MASO, G., PINNETTI, C., FRISINA, V., DALZERO, S., and RAVIZZA, M.
- Published
- 2017
5. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
- Author
-
Agweng, E, Awio, P, Bakeinyaga, G, Isabirye, C, Kabuga, U, Kasuswa, S, Katuramu, M, Kityo, C, Kiweewa, F, Kyomugisha, H, Lutalo, E, Mugyenyi, P, Mulima, D, Musana, H, Musitwa, G, Musiime, V, Ndigendawan, M, Namata, H, Nkalubo, J, Labejja, P Ocitti, Okello, P, Olal, P, Pimundu, G, Segonga, P, Ssali, F, Tamale, Z, Tumukunde, D, Namala, W, Byaruhanga, R, Kayiwa, J, Tukamushaba, J, Abunyang, S, Eram, D, Denis, O, Lwalanda, R, Mugarura, L, Namusanje, J, Nankya, I, Ndashimye, E, Nabulime, E, Senfuma, O, Bihabwa, G, Buluma, E, Easterbrook, P, Elbireer, A, Kambugu, A, Kamya, D, Katwere, M, Kiggundu, R, Komujuni, C, Laker, E, Lubwama, E, Mambule, I, Matovu, J, Nakajubi, A, Nakku, J, Nalumenya, R, Namuyimbwa, L, Semitala, F, Wandera, B, Wanyama, J, Mugerwa, H, Lugemwa, A, Ninsiima, E, Ssenkindu, T, Mwebe, S, Atwine, L, William, H, Katemba, C, Acaku, M, Ssebutinde, P, Kitizo, H, Kukundakwe, J, Naluguza, M, Ssegawa, K, Namayanja, Nsibuka, F, Tuhirirwe, P, Fortunate, M, Acen, J, Achidri, J, Amone, A, Chamai, M, Ditai, J, Kemigisa, M, Kiconco, M, Matama, C, Mbanza, D, Nambaziira, F, Odoi, M Owor, Rweyora, A, Tumwebaze, G, Kalanzi, H, Katabaazi, J, Kiyingi, A, Mbidde, M, Mugenyi, M, Mwebaze, R, Okong, P, Senoga, I, Abwola, M, Baliruno, D, Bwomezi, J, Kasede, A, Mudoola, M, Namisi, R, Ssennono, F, Tuhirwe, S, Abongomera, G, Amone, G, Abach, J, Aciro, I, Arach, B, Kidega, P, Omongin, J, Ocung, E, Odong, W, Philliam, A, Alima, H, Ahimbisibwe, B, Atuhaire, E, Atukunda, F, Bekusike, G, Bulegyeya, A, Kahatano, D, Kamukama, S, Kyoshabire, J, Nassali, A, Mbonye, A, Naturinda, T M, Ndukukire, Nshabohurira, A, Ntawiha, H, Rogers, A, Tibyasa, M, Kiirya, S, Atwongyeire, D, Nankya, A, Draleku, C, Nakiboneka, D, Odoch, D, Lakidi, L, Ruganda, R, Abiriga, R, Mulindwa, M, Balmoi, F, Kafuma, S, Moriku, E, Hakim, J, Reid, A, Chidziva, E, Musoro, G, Warambwa, C, Tinago, G, Mutsai, S, Phiri, M, Mudzingwa, S, Bafana, T, Masore, V, Moyo, C, Nhema, R, Chitongo, S, Heyderman, Robert, Kabanga, Lucky, Kaunda, Symon, Kudzala, Aubrey, Lifa, Linly, Mallewa, Jane, Moore, Mike, Mtali, Chrissie, Musowa, George, Mwimaniwa, Grace, Sikwese, Rosemary, van Oosterhout, Joep, Ziwoya, Milton, Chimbaka, H, Chitete, B, Kamanga, S, Makwakwa, T Kayinga E, Mbiya, R, Mlenga, M, Mphande, T, Mtika, C, Mushani, G, Ndhlovu, O, Ngonga, M, Nkhana, I, Nyirenda, R, Cheruiyot, P, Kwobah, C, Ekiru, W Lokitala, Mokaya, M, Mudogo, A, Nzioka, A, Siika, A, Tanui, M, Wachira, S, Wools-Kaloustian, K, Alipalli, P, Chikatula, E, Kipaila, J, Kunda, I, Lakhi, S, Malama, J, Mufwambi, W, Mulenga, L, Mwaba, P, Mwamba, E, Mweemba, A, Namfukwe, M, Kerukadho, E, Ngwatu, B, Birungi, J, Paton, N, Boles, J, Burke, A, Castle, L, Ghuman, S, Kendall, L, Hoppe, A, Tebbs, S, Thomason, M, Thompson, J, Walker, S, Whittle, J, Wilkes, H, Young, N, Spyer, M, Kapuya, C, Kyomuhendo, F, Kyakundi, D, Mkandawire, N, Mulambo, S, Senyonjo, S, Angus, B, Arenas-Pinto, A, Palfreeman, A, Post, F, Ishola, D, Arribas, J, Colebunders, R, Floridia, M, Giuliano, M, Mallon, P, Walsh, P, De Rosa, M, Rinaldi, E, Weller, I, Gilks, C, Kangewende, A, Luyirika, E, Miiro, F, Mwamba, P, Ojoo, S, Phiri, S, van Oosterhout, J, Wapakabulo, A, Peto, T, French, N, Matenga, J, Cloherty, G, van Wyk, J, Norton, M, Lehrman, S, Lamba, P, Malik, K, Rooney, J, Snowden, W, Villacian, J, Paton, Nicholas I, Kityo, Cissy, Thompson, Jennifer, Nankya, Immaculate, Bagenda, Leonard, Hoppe, Anne, Hakim, James, Kambugu, Andrew, van Oosterhout, Joep J, Kiconco, Mary, Bertagnolio, Silvia, Easterbrook, Philippa J, Mugyenyi, Peter, and Walker, A Sarah
- Published
- 2017
- Full Text
- View/download PDF
6. Italian good practice recommendations on management of persons with Long-COVID
- Author
-
Giuliano, M., Tiple, D., Agostoni, P., Armocida, B., Biardi, L., Bonfigli, A.R., Campana, A., Ciardi, M., Di Marco, F., Floridia, M., Gnerre, P., Grassi, T., Grattagliano, I., Kruger, P., Leonardi, M., Liguori, R., Pagani, E., Perger, E., Pricci, F., Ruggeri, M., Silenzi, A., Spannella, F., Tascini, C., Teté, G., Tosato, M., Vecchi, S., Villa, M., and Onder, G.
- Subjects
COVID-19 ,Long COVID ,good clinical practices (GCP) ,Italy ,health care systems ,guideline ,Public Health, Environmental and Occupational Health ,Settore MED/11 - Malattie dell'Apparato Cardiovascolare - Abstract
A significant number of people, following acute SARS-CoV-2 infection, report persistent symptoms or new symptoms that are sustained over time, often affecting different body systems. This condition, commonly referred to as Long-COVID, requires a complex clinical management. In Italy new health facilities specifically dedicated to the diagnosis and care of Long-COVID were implemented. However, the activity of these clinical centers is highly heterogeneous, with wide variation in the type of services provided, specialistic expertise and, ultimately, in the clinical care provided. Recommendations for a uniform management of Long-COVID were therefore needed. Professionals from different disciplines (including general practitioners, specialists in respiratory diseases, infectious diseases, internal medicine, geriatrics, cardiology, neurology, pediatrics, and odontostomatology) were invited to participate, together with a patient representative, in a multidisciplinary Panel appointed to draft Good Practices on clinical management of Long-COVID. The Panel, after extensive literature review, issued recommendations on 3 thematic areas: access to Long-COVID services, clinical evaluation, and organization of the services. The Panel highlighted the importance of providing integrated multidisciplinary care in the management of patients after SARS-CoV-2 infection, and agreed that a multidisciplinary service, one-stop clinic approach could avoid multiple referrals and reduce the number of appointments. In areas where multidisciplinary services are not available, services may be provided through integrated and coordinated primary, community, rehabilitation and mental health services. Management should be adapted according to the patient’s needs and should promptly address possible life-threatening complications. The present recommendations could provide guidance and support in standardizing the care provided to Long-COVID patients.
- Published
- 2023
7. Usefulness of calcaneal quantitative ultrasound stiffness for the evaluation of bone health in HIV-1-infected subjects: comparison with dual X-ray absorptiometry
- Author
-
Fantauzzi A, Floridia M, Ceci F, Cacciatore F, Vullo V, and Mezzaroma I
- Subjects
Bone mineral density ,Fracture risk ,Calcaneal quantitative ultrasound ,Osteoporosis ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Alessandra Fantauzzi,1 Marco Floridia,2 Fabrizio Ceci,3 Francesco Cacciatore,4 Vincenzo Vullo,5 Ivano Mezzaroma1 1Department of Clinical Medicine, Sapienza – University of Rome, 2Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità (ISS), 3Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, 4U.O. of Cardiac Rehabilitation, Fondazione Salvatore Maugeri, IRCCS, Istituto di Telese Terme, Benevento, 5Department of Public Health and Infectious Diseases, Sapienza – University of Rome, Rome, Italy Objectives: With the development of effective treatments and the resulting increase in life expectancy, bone mineral density (BMD) alteration has emerged as an important comorbidity in human immunodeficiency virus type-1 (HIV-1)-infected individuals. The potential contributors to the pathogenesis of osteopenia/osteoporosis include a higher prevalence of risk factors, combined antiretroviral therapy (cART)-exposure, HIV-1 itself and chronic immune activation/inflammation. Dual-energy X-ray absorptiometry (DXA) is the “gold standard” technique for assessing bone status in HIV-1 population. Methods: We conducted a cross-sectional study to investigate bone mineral status in a group of 158 HIV-1-infected subjects. The primary endpoint was the feasibility of calcaneal quantitative ultrasound (QUS) as a screening tool for BMD. All subjects were receiving stable cART and were virologically suppressed (HIV-RNA
- Published
- 2016
8. CD4/CD8 ratio in pregnant women with HIV and its association with pregnancy outcome: data from a national study in Italy
- Author
-
Floridia, M., Pinnetti, C., Masuelli, G., Spinillo, A., Savasi, V. M., Liuzzi, G., Degli Antoni, A. M., Sansone, M., Guaraldi, G., Dalzero, S., Maso, G., Francisci, D., Sterrantino, G., Ravizza, M., Tamburrini, E., Di Lorenzo, F., Meli, M., Campolmi, I., Vichi, F., Del Pin, B., Marocco, R., Mastroianni, C., Mercurio, V. S., Zanaboni, D., Nardini, G., Stentarelli, C., Beghetto, B., Molinari, A., Crisalli, M. P., Donisi, A., Ruggieri, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Paradiso, L., Forlanini, F., Longoni, E., Placido, G., Milini, P., Savalli, F., Sabbatini, F., Papalini, C., Bernini, L., Grossi, P., Rizzi, L., Portelli, V., Bernardon, M., Bussolaro, S., Della Pieta, I., Sorz, A., Meloni, A., Chiodo, A., Dedoni, M., Ortu, F., Piano, P., Citernesi, A., Bordoni Vicini, I., Luzi, K., Roccio, M., Vimercati, A., Calabretti, D., Gigante, S., Guerra, B., Cervi, F., Simonazzi, G., Margarito, E., Capretti, M. G., Marsico, C., Faldella, G., Martinelli, P., Agangi, A., Capone, A., Maruotti, G. M., Tibaldi, C., Trentini, L., Todros, T., Frisina, V., Savasi, V., Cardellicchio, E., Giaquinto, C., Fiscon, M., Rubino, E., Franceschetti, L., Badolato, R., Forleo, M. A., Tassis, B., Ruggiero, M., Genovese, O., Cafforio, C., Casadei, A. M., Cavaliere, A. F., Cellini, M., Marconi, A. M., Ierardi, M., Simonetti, S. C., Alfieri, N., Agrati, S., Polizzi, C., Mattei, A., Pirillo, M. F., Amici, R., Galluzzo, C. M., Donnini, S., Baroncelli, S., Cerioli, A., De Martino, M., Parazzini, F., Vella, S., Floridia M., Pinnetti C., Masuelli G., Spinillo A., Savasi V.M., Liuzzi G., Degli Antoni A.M., Sansone M., Guaraldi G., Dalzero S., Maso G., Francisci D., Sterrantino G., Ravizza M., Tamburrini E., Di Lorenzo F., Meli M., Campolmi I., Vichi F., Del Pin B., Marocco R., Mastroianni C., Mercurio V.S., Zanaboni D., Nardini G., Stentarelli C., Beghetto B., Molinari A., Crisalli M.P., Donisi A., Ruggieri A., Piepoli M., Cerri V., Zuccotti G., Giacomet V., Paradiso L., Forlanini F., Longoni E., Placido G., Milini P., Savalli F., Sabbatini F., Papalini C., Bernini L., Grossi P., Rizzi L., Portelli V., Bernardon M., Bussolaro S., Della Pieta I., Sorz A., Meloni A., Chiodo A., Dedoni M., Ortu F., Piano P., Citernesi A., Bordoni Vicini I., Luzi K., Roccio M., Vimercati A., Calabretti D., Gigante S., Guerra B., Cervi F., Simonazzi G., Margarito E., Capretti M.G., Marsico C., Faldella G., Martinelli P., Agangi A., Capone A., Maruotti G.M., Tibaldi C., Trentini L., Todros T., Frisina V., Savasi V., Cardellicchio E., Giaquinto C., Fiscon M., Rubino E., Franceschetti L., Badolato R., Forleo M.A., Tassis B., Ruggiero M., Genovese O., Cafforio C., Casadei A.M., Cavaliere A.F., Cellini M., Marconi A.M., Ierardi M., Simonetti S.C., Alfieri N., Agrati S., Polizzi C., Mattei A., Pirillo M.F., Amici R., Galluzzo C.M., Donnini S., Baroncelli S., Cerioli A., De Martino M., Parazzini F., and Vella S.
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Multivariate analysis ,030106 microbiology ,CD4-CD8 Ratio ,Human immunodeficiency virus (HIV) ,HIV Infections ,CD8-Positive T-Lymphocytes ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,CD4/CD8 ratio ,Pregnancy ,CD4 ,CD8 ,HIV suppression ,Preterm delivery ,Female ,Humans ,Infant, Newborn ,Pregnancy Outcome ,Pregnant Women ,Viral Load ,Pregnancy Complications, Infectious ,medicine ,030212 general & internal medicine ,business.industry ,Obstetrics ,Infectious ,Infant ,General Medicine ,Newborn ,medicine.disease ,Pregnancy Complications ,Infectious Diseases ,Increased risk ,National study ,Outcome data ,business - Abstract
Purpose: To evaluate associations between CD4/CD8 ratio and pregnancy outcomes in women with HIV. Methods: We evaluated, in a national study of pregnant women with HIV receiving antiretroviral treatment (ART), values of CD4/CD8 ratio at entry in pregnancy, changes between first and third trimester, and possible associations with preterm delivery, low birthweight, and HIV-RNA < 50 copies/ml at third trimester in univariate and multivariate analyses. Results: Among 934 women, 536 (57.4%) were already on ART at conception. CD4/CD8 ratio (baseline value 0.570) increased significantly between the first and third trimesters, particularly in women who started ART in pregnancy (+ 0.163, vs. + 0.036 in women already on treatment). The rate of CD4/CD8 ratio normalization, defined by achieving a ratio ≥ 1 at the third trimester, was 13.2%. In multivariable analyses, women who entered pregnancy with a CD4/CD8 ratio < 0.3, compared to women with ratio ≥ 1, were almost four-times less likely to have third-trimester HIV-RNA < 50 copies/ml (AOR 0.258, 95%CI 0.111–0.601), and more than twice as likely to have preterm delivery (AOR 2.379, 95%CI 1.082–5.232). For preterm delivery, also a baseline CD4/CD8 ratio between 0.3 and 0.45 was significantly associated with an increased risk (AOR: 3.415, 95%CI 1.690–6.900). Conclusion: We described for the first time independent associations of low CD4/CD8 ratio with preterm delivery and HIV-RNA suppression.
- Published
- 2021
9. SHORT REPORT: Declining HCV seroprevalence in pregnant women with HIV
- Author
-
FLORIDIA, M., TAMBURRINI, E., ANZIDEI, G., TIBALDI, C., MUGGIASCA, M. L., GUARALDI, G., FISCON, M., VIMERCATI, A., MARTINELLI, P., DONISI, A., DALZERO, S., and RAVIZZA, M.
- Published
- 2010
10. Treatment with Protease Inhibitors and Coinfection with Hepatitis C Virus Are Independent Predictors of Preterm Delivery in HIV-Infected Pregnant Women [with Reply]
- Author
-
Ravizza, M., Martinelli, P., Bucceri, A., Fiore, S., Alberico, S., Tamburrini, E., Tibaldi, C., Guaraldi, G., Anzidei, G., Maccabruni, A., Crisalli, M. P., Floridia, M., Cotter, Amanda M., and O'Sullivan, Mary J.
- Published
- 2007
- Full Text
- View/download PDF
11. Good prenatal detection rate of major birth defects in HIV-infected pregnant women in Italy
- Author
-
Floridia, M., Mastroiacovo, P., Ravizza, M., Todros, T., Chiadò Fiorio Tin, M., Marconi, A. M., Cetin, I., Maruotti, G. M., Liuzzi, G., Pinnetti, C., Degli Antoni, A., Spinillo, A., Guerra, B., and Tamburrini, E.
- Published
- 2015
- Full Text
- View/download PDF
12. Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study
- Author
-
Floridia, M., Masuelli, G., Ravizza, M., Tassis, B., Cetin, I., Sansone, M., Antoni, A. D., Simonazzi, G., Maccabruni, A., Francisci, D., Frisina, V., Liuzzi, G., Dalzero, S., Tamburrini, E., Di Lorenzo, F., Sterrantino, G., Meli, M., Campolmi, I., Vichi, F., Del Pin, B., Marocco, R., Mastroianni, C., S. Mercurio V., Zanaboni, D., Guaraldi, G., Nardini, G., Stentarelli, C., Beghetto, B., Antoni, A. M. D., Molinari, A., Crisalli, M. P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Coletto, S., Di Nello, F., Madia, C., Placido, G., Milini, P., Savalli, F., Portelli, V., Sabbatini, F., Papalini, C., Bernini, L., Grossi, P., Rizzi, L., Bernardon, M., Maso, G., Rizzante, E., Belcaro, C., Meloni, A., Dedoni, M., Ortu, F., Piano, P., Citernesi, A., Bordonivicini, I., Luzi, K., Spinillo, A., Roccio, M., Vimercati, A., Crupano, F. M., Calabretti, D., Cervi, F., Margarito, E., Capretti, M. G., Marsico, C., Faldella, G., Martinelli, P., Agangi, A., Capone, A., Maruotti, G. M., Tibaldi, C., Trentini, L., Todros, T., Brambilla, T., Savasi, V., Personeni, C., Giaquinto, C., Fiscon, M., Rubino, E., Franceschetti, L., Badolato, R., Tiso, G. C., Genovese, O., Cafforio, C., Pinnetti, C., Casadei, A. M., Cavaliere, A. F., Cellini, M., Marconi, A. M., Sacchi, V., Ierardi, M., Polizzi, C., Mattei, A., Pirillo, M. F., Amici, R., Galluzzo, C. M., Donnini, S., Baroncelli, S., Villani, P., Cusato, M., Cerioli, A., De Martino, M., Parazzini, F., Vella, S., Floridia, M., Masuelli, G., Ravizza, M., Tassis, B., Cetin, I., Sansone, M., Antoni, A. Degli, Simonazzi, G., Maccabruni, A., Francisci, D., Frisina, V., Liuzzi, G., Dalzero, S., Tamburrini, E., Di Lorenzo, F., Sterrantino, G., Meli, M., Campolmi, I., Vichi, F., Del Pin, B., Marocco, R., Mastroianni, C., S.Mercurio, V., Zanaboni, D., Guaraldi, G., Nardini, G., Stentarelli, C., Beghetto, B., Antoni, A.M. Degli, Molinari, A., Crisalli, M.P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Coletto, S., Di Nello, F., Madia, C., Placido, G., Milini, P., Savalli, F., Portelli, V., Sabbatini, F., Papalini, C., Bernini, L., Grossi, P., Rizzi, L., Bernardon, M., Maso, G., Rizzante, E., Belcaro, C., Meloni, A., Dedoni, M., Ortu, F., Piano, P., Citernesi, A., BordoniVicini, I., Luzi, K., Spinillo, A., Roccio, M., Vimercati, A., Crupano, F.M., Calabretti, D., Cervi, F., Margarito, E., Capretti, M.G., Marsico, C., Faldella, G., Martinelli, P., Agangi, A., Capone, A., Maruotti, G.M., Tibaldi, C., Trentini, L., Todros, T., Brambilla, T., Savasi, V., Personeni, C., Giaquinto, C., Fiscon, M., Rubino, E., Franceschetti, L., Badolato, R., Tiso, G.C., Genovese, O., Cafforio, C., Pinnetti, C., Casadei, A.M., Cavaliere, A.F., Cellini, M., Marconi, A.M., Sacchi, V., Ierardi, M., Polizzi, C., Mattei, A., Pirillo, M.F., Amici, R., Galluzzo, C.M., Donnini, S., Baroncelli, S., Villani, P., Cusato, M., Cerioli, A., De Martino, M., Parazzini, F., and Vella, S.
- Subjects
Male ,0301 basic medicine ,medicine.medical_treatment ,HIV Infections ,0302 clinical medicine ,Pregnancy ,Pharmacology (medical) ,030212 general & internal medicine ,Pregnancy Complications, Infectious ,Darunavir ,medicine.diagnostic_test ,Obstetrics ,Pregnancy Outcome ,virus diseases ,Alanine Transaminase ,Viral Load ,Cholesterol ,Treatment Outcome ,Infectious Diseases ,Premature birth ,Gestation ,Female ,Drugs in pregnancy ,medicine.drug ,Adult ,Microbiology (medical) ,medicine.medical_specialty ,Drug-Related Side Effects and Adverse Reactions ,Anti-HIV Agents ,Atazanavir Sulfate ,Settore MED/17 - MALATTIE INFETTIVE ,03 medical and health sciences ,pharmacology ,pharmacology (medical) ,infectious diseases ,medicine ,Humans ,Caesarean section ,Triglycerides ,Pharmacology ,business.industry ,Infant, Newborn ,Infant ,Bilirubin ,medicine.disease ,030112 virology ,Atazanavir ,azatanavir sulfate ,Lipid profile ,business - Abstract
Background Atazanavir and darunavir represent the main HIV PIs recommended in pregnancy, but comparative data in pregnant women are limited. We assessed the safety and activity profile of these two drugs in pregnancy using data from a national observational study. Methods Women with atazanavir or darunavir exposure in pregnancy were evaluated for laboratory measures and main pregnancy outcomes (e.g. preterm delivery, low birthweight, non-elective caesarean section and neonatal gestational age-adjusted birthweight Z-score). Results Final analysis included 500 pregnancies with either atazanavir (n = 409) or darunavir (n = 91) exposure. No differences in pregnancy outcomes, weight gain in pregnancy, drug discontinuations, undetectable HIV-RNA, haemoglobin, ALT, total cholesterol, HDL cholesterol and LDL cholesterol were observed between the two groups. At third trimester, exposure to darunavir was associated with higher levels of plasma triglycerides (median 235.5 versus 179 mg/dL; P = 0.032) and a higher total cholesterol/HDL cholesterol ratio (median 4.03 versus 3.27; P = 0.028) and exposure to atazanavir was associated with higher levels of plasma bilirubin (1.54 versus 0.32 mg/dL; P
- Published
- 2017
13. Weight Gain during Pregnancy in Women with HIV Receiving Different Antiretroviral Regimens
- Author
-
Floridia, M., Masuelli, G., Tassis, B., Franceschetti, L., Savasi, V. M., Spinillo, A., Tamburrini, E., Guaraldi, G., Dalzero, S., Sansone, M., Chiodo, A., Degli Antoni, A. M., Pinnetti, C., Liuzzi, G., Ravizza, M., Di Lorenzo, F., Sterrantino, G., Meli, M., Campolmi, I., Vichi, F., Del Pin, B., Marocco, R., Mastroianni, C., Mercurio, V. S., Zanaboni, D., Nardini, G., Stentarelli, C., Beghetto, B., Molinari, A., Crisalli, M. P., Donisi, A., Ruggieri, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Paradiso, L., Forlanini, F., Longoni, E., Placido, G., Milini, P., Savalli, F., Portelli, V., Sabbatini, F., Francisci, D., Papalini, C., Bernini, L., Grossi, P., Rizzi, L., Maso, G., Bernardon, M., Bussolaro, S., della Pieta, I., Sorz, A., Meloni, A., Dedoni, M., Ortu, F., Piano, P., Citernesi, A., Vicini, I. B., Luzi, K., Roccio, M., Vimercati, A., Calabretti, D., Gigante, S., Guerra, B., Cervi, F., Simonazzi, G., Margarito, E., Capretti, M. G., Marsico, C., Faldella, G., Martinelli, P., Agangi, A., Capone, A., Maruotti, G. M., Tibaldi, C., Trentini, L., Todros, T., Frisina, V., Cardellicchio, E., Giaquinto, C., Fiscon, M., Rubino, E., Badolato, R., Forleo, M. A., Ruggiero, M., Genovese, O., Cafforio, C., Casadei, A. M., Cavaliere, A. F., Cellini, M., Marconi, A. M., Ierardi, M., Simonetti, S. C., Alfieri, N., Agrati, S., Polizzi, C., Mattei, A., Pirillo, M. F., Amici, R., Galluzzo, C. M., Donnini, S., Baroncelli, S., Cerioli, A., de Martino, M., Parazzini, F., and Vella, S.
- Subjects
medicine.medical_specialty ,Multivariate analysis ,Anti-HIV Agents ,Integrase inhibitor ,HIV Infections ,Overweight ,Weight Gain ,Cohort Studies ,Pregnancy ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Settore MED/38 - Pediatria Generale e Specialistica ,Pharmacology ,business.industry ,Weight change ,Odds ratio ,medicine.disease ,Obesity ,Infectious Diseases ,Reverse Transcriptase Inhibitors ,Female ,medicine.symptom ,business ,Weight gain - Abstract
Background No published studies have evaluated in pregnant women with HIV weight gain with different antiretroviral drug classes. Methods Data from a national cohort study were used. We compared absolute weight gain and occurrence of excessive weight gain in women with HIV who received during pregnancy integrase inhibitors (INSTI), protease inhibitors (PI), or non-nucleoside reverse transcriptase inhibitors (NNRTI). Excessive weight gain was defined according to the Institute of Medicine recommendations. Possible predictors of weight gain were assessed using univariate and multivariate analyses. Results Among 273 cases (PI: 191, NNRTI: 43, INSTI: 39), the mean weight increase was 11.3 kg, and 25.4% of the mothers had an excessive weight increase. No significant differences were found among the three treatment groups for absolute weight increase, occurrence of excessive weight gain, infant birthweight, and other pregnancy and laboratory outcomes. The comparisons of individual drugs, although based on a limited number of cases, suggested no major differences. A significant positive correlation was found between weight gain and CD4+ T-cell increase during pregnancy. In multivariate analyses, drug class and nucleoside backbone were not associated with absolute or excessive weight increase. Excessive weight increase was significantly associated with week of delivery (adjusted odds ratio: 1.74, 95% CI 1.15, 2.63), obesity (5.21, 95% CI 1.85, 14.64), overweight (7.95, 95% CI 3.26, 19.39), recent substance use (5.96, 95% CI 1.13, 31.40) and fasting 2nd trimester hyperglycaemia (3.94, 95% CI 1.14, 13.65). Conclusions No significant differences in absolute weight change or occurrence of excessive weight gain were found among women with HIV who received during pregnancy different classes of antiretroviral drugs.
- Published
- 2021
14. Comorbidity status of deceased COVID-19 in-patients in Italy
- Author
-
Vetrano, D. L., Tazzeo, C., Palmieri, L., Marengoni, A., Zucchelli, A., Lo Noce, C., Onder, G., Andrianou, X., Barbariol, P., Bella, A., Bellino, S., Benelli, E., Bertinato, L., Boros, S., Brambilla, G., Calcagnini, G., Canevelli, M., Castrucci, M. R., Censi, F., Ciervo, A., Colaizzo, E., D'Ancona, F., Del Manso, M., Di Benedetto, C., Donfrancesco, C., Fabiani, M., Facchiano, F., Filia, A., Floridia, M., Galati, F., Giuliano, M., Grisetti, T., Kodra, Y., Langer, M., Lega, I., Maiozzi, P., Malchiodi Albedi, F., Manno, V., Martini, M., Urdiales, A. M., Mattei, E., Meduri, C., Meli, P., Minelli, G., Nebuloni, M., Nistico, L., Nonis, M., Palmisano, L., Petrosillo, N., Pezzotti, P., Pricci, F., Punzo, O., Puro, V., Raparelli, V., Rezza, G., Riccardo, F., Rota, M. C., Salerno, P., Serra, D., Siddu, A., Stefanelli, P., Tamburo de Bella, M., Tiple, D., Unim, B., Vaianella, L., Vanacore, N., Vichi, M., Villani, E. R., Zona, A., and Brusaferro, S.
- Subjects
Aging ,medicine.medical_specialty ,Short Communication ,Disease ,Type 2 diabetes ,Comorbidity ,Chronic disease ,NO ,03 medical and health sciences ,0302 clinical medicine ,COVID-19 ,Mortality ,Multimorbidity ,Risk Factors ,Internal medicine ,medicine ,80 and over ,Diabetes Mellitus ,Dementia ,Humans ,030212 general & internal medicine ,Stroke ,Aged ,Aged, 80 and over ,COPD ,business.industry ,SARS-CoV-2 ,Atrial fibrillation ,Italy ,Diabetes Mellitus, Type 2 ,medicine.disease ,030228 respiratory system ,Heart failure ,Geriatrics and Gerontology ,business ,Type 2 - Abstract
Background Most COVID-19-related deaths have occurred in older persons with comorbidities. Specific patterns of comorbidities related to COVID-19 deaths have not been investigated. Methods A random sample of 6085 individuals in Italy who died in-hospital with confirmed COVID-19 between February and December 2020 were included. Observed to expected (O/E) ratios of disease pairs were computed and logistic regression models were used to determine the association between disease pairs with O/E values ≥ 1.5. Results Six pairs of diseases exhibited O/E values ≥ 1.5 and statistically significant higher odds of co-occurrence in the crude and adjusted analyses: (1) ischemic heart disease and atrial fibrillation, (2) atrial fibrillation and heart failure, (3) atrial fibrillation and stroke, (4) heart failure and COPD, (5) stroke and dementia, and (6) type 2 diabetes and obesity. Conclusion In those deceased in-hospital due to COVID-19 in Italy, disease combinations defined by multiple cardio-respiratory, metabolic, and neuropsychiatric diseases occur more frequently than expected. This finding indicates a need to investigate the possible role of these clinical profiles in the chain of events that lead to death in individuals who have contracted SARS-CoV-2.
- Published
- 2021
15. Rate, Predictors, and Consequences of Late Antenatal Booking in a National Cohort Study of Pregnant Women With HIV in Italy
- Author
-
Floridia, M., Pinnetti, C., Ravizza, M., Frisina, V., Cetin, I., Fiscon, M., Sansone, M., Antoni, Degli A., Guaraldi, G., Vimercati, A., Guerra, B., Placido, G., Dalzero, S., and Tamburrini, E.
- Published
- 2014
16. Efficacy and Safety of Atazanavir in Patients with End-Stage Liver Disease
- Author
-
Guaraldi, G., Cocchi, S., Motta, A., Ciaffi, S., Codeluppi, M., Bonora, S., Di Benedetto, F., Masetti, M., Floridia, M., Baroncelli, S., Pinetti, D., Bertolini, A., Gerunda, G. E., and Esposito, R.
- Published
- 2009
- Full Text
- View/download PDF
17. Vaginal delivery in women with HIV in Italy: results of 5 years of implementation of the national SIGO-HIV protocol
- Author
-
Tibaldi, C., Masuelli, G., Sansone, M., Tassis, B., Cetin, I., Franceschetti, L., Spinillo, A., Simonazzi, G., Vimercati, A., Dalzero, S., Meloni, A., Bernardon, M., Frisina, V., Polizzi, C., Todros, T., Martinelli, P., Floridia, M., Ravizza, M., Trentini, L., Tiso, G., Brambilla, T., Savasi, V., Personeni, C., Zuccotti, G., Giacomet, V., Coletto, S., Di Nello, F., Madia, C., Forleo, M. A., Badolato, R., Roccio, M., Zanaboni, D., Sirico, A., Maruotti, G. M., Capone, A., Guerra, B., Cervi, F., Margarito, E., Capretti, M. G., Marsico, C., Faldella, G., Crupano, F. M., Calabretti, D., Ravizz, M., Marconi, A. M., Galiano, V., Ierardi, S. C. S. M., Chiodo, A., Ortu, F., Piano, P., Dedoni, I. M., Maso, G., Belcaro, C., Rizzante, E., Alberico, S., Citernesi, A., Vicini, I. B., Luzi, K., Tibaldi C, Masuelli G, Sansone M, Tassis B, Cetin I, Franceschetti L, Spinillo A, Simonazzi G, Vimercati A, Dalzero S, Meloni A, Bernardon M, Frisina V, Polizzi C, Todros T, Martinelli P, Floridia M, Ravizza M, and for SIGO-HIV Study Group.
- Subjects
0301 basic medicine ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,030106 microbiology ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Pregnancy ,medicine ,Humans ,030212 general & internal medicine ,Young adult ,Hiv transmission ,Delivery complications ,Vaginal delivery ,business.industry ,Obstetrics ,Cesarean Section ,HIV ,Mode of delivery ,Delivery, Obstetric ,Female ,Italy ,Viral Load ,Obstetric ,General Medicine ,medicine.disease ,Infectious Diseases ,Delivery complication ,business ,Viral load ,Delivery - Abstract
PURPOSE: To evaluate the maternal and neonatal safety of vaginal delivery in women with HIV following the implementation of a national protocol in Italy. METHODS: Vaginal delivery was offered to all eligible women who presented antenatally at twelve participating clinical sites. Data collection and definition of outcomes followed the procedures of the National Program on Surveillance on Antiretroviral Treatment in Pregnancy. Pregnancy outcomes were compared according to the mode of delivery, classified as vaginal, elective cesarean (ECS) and non-elective cesarean section (NECS). RESULTS: Among 580 women who delivered between January 2012 and September 2017, 142 (24.5%) had a vaginal delivery, 323 (55.7%) had an ECS and 115 (19.8%) had an NECS. The proportion of vaginal deliveries increased significantly over time, from 18.9% in 2012 to 35.3% in 2017 (p
- Published
- 2019
18. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001–2011
- Author
-
Floridia, M, Mastroiacovo, P, Tamburrini, E, Tibaldi, C, Todros, T, Crepaldi, A, Sansone, M, Fiscon, M, Liuzzi, G, Guerra, B, Vimercati, A, Vichi, F, Vicini, I, Pinnetti, C, Marconi, A M, and Ravizza, M
- Published
- 2013
- Full Text
- View/download PDF
19. COVID-19 mortality among migrants living in Italy
- Author
-
Canevelli, M., Palmieri, L., Raparelli, V., Punzo, O., Donfrancesco, C., Noce, C. L., Vanacore, N., Brusaferro, S., Onder, G., Bertinato, L., Bram-billa, G., Calcagnini, G., Kneves, Q., Censi, F., Colaizzo, E., Facchiano, F. -S., Floridia, M., Giuliano, M., Grisetti, T. -Z., Kodra, Y., Langer, M., Lega, I., Lo Noce, C., Albedi, F. M., Manno, V., Mattei, E., Meli, P., Minelli, G., Nebuloni, M., Nistico, L., Nonis, M., Palmisano, L., Petrosillo, N., Pricci, F., Salerno, P., Tamburo De Bella, M., Taru-scio, D., Tiple, D., Unim, B., Vaianella, L., Vichi, M., Villani, E. R., and Zona, A.
- Subjects
Adult ,Male ,Chronic Obstructive ,Global health ,Comorbidity ,Pulmonary Disease ,Betacoronavirus ,Age Distribution ,Cause of Death ,Neoplasms ,80 and over ,Diabetes Mellitus ,Humans ,Obesity ,Viral ,Renal Insufficiency ,Mortality ,Chronic ,COVID-19 ,Migration ,SARS-CoV-2 ,Aged ,Aged, 80 and over ,Albania ,Cardiovascular Diseases ,Coronavirus Infections ,Diabetes Mellitus, Type 2 ,Female ,France ,Healthy Worker Effect ,Hospital Records ,Italy ,Middle Aged ,Pneumonia, Viral ,Pulmonary Disease, Chronic Obstructive ,Renal Insufficiency, Chronic ,Transients and Migrants ,Pandemics ,Pneumonia ,Type 2 - Published
- 2020
20. Prevalence and clinical correlates of dementia among COVID-19-related deaths in Italy
- Author
-
Canevelli, M., Palmieri, L., Raparelli, V., Lo Noce, C., Colaizzo, E., Tiple, D., Vaianella, L., Vanacore, N., Brusaferro, S., Onder, G., Bertinato, L., Brambilla, G., Calcagnini, G., Censi, F., Donfrancesco, C., Facchiano, F., Floridia, M., Giuliano, M., Grisetti, T., Kodra, Y., Langer, M., Lega, I., Albedi, F. M., Manno, V., Mattei, E., Meli, P., Minelli, G., Nebuloni, M., Nistico, L., Nonis, M., Palmisano, L., Petrosillo, N., Pricci, F., Punzo, O., Salerno, P., Debella, M. T., Taruscio, D., Unim, B., Vichi, M., Villani, E. R., and Zona, A.
- Subjects
medicine.medical_specialty ,Pediatrics ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Clinical Neurology ,Short Report ,lcsh:Geriatrics ,lcsh:RC346-429 ,SARS‐CoV‐2 ,NO ,03 medical and health sciences ,0302 clinical medicine ,COVID‐19 ,Intensive care ,Medicine ,Dementia ,lcsh:Neurology. Diseases of the nervous system ,030304 developmental biology ,Diagnostic Assessment & Prognosis ,0303 health sciences ,business.industry ,SARS-CoV-2 ,Public health ,COVID-19 ,dementia ,public health ,Cognition ,medicine.disease ,lcsh:RC952-954.6 ,Psychiatry and Mental health ,Concomitant ,Population study ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
Introduction We aimed at exploring the proportion of patients dying with COVID‐19 and concomitant dementia in Italy, as well as their clinical characteristics and trajectories of care. Methods The proportion of COVID‐19‐related deaths occurring in people with dementia and the clinical characteristics of deceased individuals according to their dementia status were explored by considering the medical charts of a representative sample of patients deceased in Italian hospitals (n = 2621). Results A total of 415 individuals with dementia were identified in the study population, accounting for 15.8% of overall COVID‐19‐related deaths. Patients with dementia less frequently presented with cough, had lower chance of receiving supportive therapies and intensive care approaches, and showed a faster clinical worsening as compared with individuals with intact cognition. Discussion Dementia confers a relevant risk of adverse outcomes in case of SARS‐CoV‐2 infection and influences the clinical presentation, course and management of affected individuals.
- Published
- 2020
21. Sex differences in clinical phenotype and transitions of care among individuals dying of COVID-19 in Italy
- Author
-
Raparelli, V., Palmieri, L., Canevelli, M., Pricci, F., Unim, B., Lo Noce, C., Villani, E. R., Rochon, P. A., Pilote, L., Vanacore, N., Onder, G., Agazio, E., Andrianou, X., Barbariol, P., Bella, A., Bellino, S., Benelli, E., Bertinato, L., Boros, S., Brambilla, G., Calcagnini, G., Daqar, Q. Z., Castrucci, M. R., Censi, F., Ciervo, A., Colaizzo, E., D'Ancona, F., Delmanso, M., Donfrancesco, C., Fabiani, M., Facchiano, F., Filia, A., Floridia, M., Galati, F., Giuliano, M., Grisetti, T., Kodra, Y., Langer, M., Lega, I., Lonoce, C., Maiozzi, P., Malchiodialbedi, F., Manno, V., Martini, M., Urdiales, A. M., Mattei, E., Meduri, C., Meli, P., Minelli, G., Nebuloni, M., Nistico, L., Nonis, M., Palmisano, L., Petrosillo, N., Pezzotti, P., Punzo, O., Puro, V., Rezza, G., Riccardo, F., Rota, M. C., Salerno, P., Serra, D., Siddu, A., Stefanelli, P., Tamburo DeBella, M., Tiple, D., Vaianella, L., Vichi, M., Zona, A., and Brusaferro, S.
- Subjects
Male ,Multivariate analysis ,covid-19 ,comorbidities ,in-hospital complications ,sex ,transition of care ,lcsh:Medicine ,Disease ,Comorbidity ,030204 cardiovascular system & hematology ,Comorbidities ,COVID-19 ,In-hospital complications ,Sex ,Transition of care ,lcsh:Physiology ,Aged ,Aged, 80 and over ,Betacoronavirus ,Coronavirus Infections ,Female ,Hospitalization ,Humans ,Italy ,Middle Aged ,Multimorbidity ,Multivariate Analysis ,Pandemics ,Patient Transfer ,Pneumonia, Viral ,Prevalence ,Retrospective Studies ,Risk Factors ,SARS-CoV-2 ,Sex Factors ,0302 clinical medicine ,Endocrinology ,80 and over ,030212 general & internal medicine ,Viral ,lcsh:QP1-981 ,Acute kidney injury ,medicine.medical_specialty ,NO ,Gender Studies ,03 medical and health sciences ,Internal medicine ,medicine ,Dementia ,business.industry ,Research ,lcsh:R ,Outbreak ,Retrospective cohort study ,Pneumonia ,medicine.disease ,business ,Kidney disease - Abstract
Background Among the unknowns posed by the coronavirus disease 2019 (COVID-19) outbreak, the role of biological sex to explain disease susceptibility and progression is still a matter of debate, with limited sex-disaggregated data available. Methods A retrospective analysis was performed to assess if sex differences exist in the clinical manifestations and transitions of care among hospitalized individuals dying with laboratory-confirmed SARS-CoV-2 infection in Italy (February 27–June 11, 2020). Clinical characteristics and the times from symptoms’ onset to admission, nasopharyngeal swab, and death were compared between sexes. Adjusted multivariate analysis was performed to identify the clinical features associated with male sex. Results Of the 32,938 COVID-19-related deaths that occurred in Italy, 3517 hospitalized and deceased individuals with COVID-19 (mean 78 ± 12 years, 33% women) were analyzed. At admission, men had a higher prevalence of ischemic heart disease (adj-OR = 1.76, 95% CI 1.39–2.23), chronic obstructive pulmonary disease (adj-OR = 1.7, 95% CI 1.29–2.27), and chronic kidney disease (adj-OR = 1.48, 95% CI 1.13–1.96), while women were older and more likely to have dementia (adj-OR = 0.73, 95% CI 0.55–0.95) and autoimmune diseases (adj-OR = 0.40, 95% CI 0.25–0.63), yet both sexes had a high level of multimorbidity. The times from symptoms’ onset to admission and nasopharyngeal swab were slightly longer in men despite a typical acute respiratory illness with more frequent fever at the onset. Men received more often experimental therapy (adj-OR = 2.89, 95% CI 1.45–5.74) and experienced more likely acute kidney injury (adj-OR = 1.47, 95% CI 1.13–1.90). Conclusions Men and women dying with COVID-19 had different clinical manifestations and transitions of care. Identifying sex-specific features in individuals with COVID-19 and fatal outcome might inform preventive strategies.
- Published
- 2020
22. Amniocentesis and chorionic villus sampling in HIV-infected pregnant women: a multicentre case series
- Author
-
Floridia M, Masuelli G, Meloni A, Cetin I, Tamburrini E, Cavaliere AF, Dalzero S, Sansone M, Alberico S, Guerra B, Spinillo A, Chiadò Fiorio Tin M, Ravizza M, Mori F, Ortolani P, Dalle Nogare ER, Di Lorenzo F, Sterrantino G, Meli M, Polemi S, Nocentini J, Baldini M, Montorzi G, Mazzetti M, Rogasi P, Borchi B, Vichi F, Del Pin B, Pinter E, Anzalone E, Marocco R, Mastroianni C, Mercurio VS, Carocci A, Grilli E, Maccabruni A, Zaramella M, Mariani B, Natalini Raponi G, Guaraldi G, Nardini G, Stentarelli C, Beghetto B, Degli Antoni AM, Molinari A, Crisalli MP, Donisi A, Piepoli M, Cerri V, Zuccotti G, Giacomet V, Coletto S, Di Nello F, Madia C, Placido G, Vivarelli A, Castelli P, Savalli F, Portelli V, Sabbatini F, Francisci D, Bernini L, Grossi P, Rizzi L, Maso G, Airoud M, Soppelsa G, Dedoni M, Cuboni C, Ortu F, Piano P, Citernesi A, Bordoni Vicini I, Luzi K, Roccio M, Vimercati A, Miccolis A, De Gennaro A, Cervi F, Simonazzi G, Margarito E, Capretti MG, Marsico C, Faldella G, Martinelli P, Agangi A, Capone A, Maruotti GM, Tibaldi C, Trentini L, Todros T, Frisina V, Brambilla T, Savasi V, Personeni C, Giaquinto C, Fiscon M, Rubino E, Bucceri A, Matrone R, Scaravelli G, Genovese O, Cafforio C, Pinnetti C, Liuzzi G, Tozzi V, Massetti P, Casadei AM, Cellini M, Castelli Gattinara G, Marconi AM, Sacchi V, Ierardi M, Polizzi C, Mattei A, Pirillo MF, Amici R, Galluzzo CM, Donnini S, Baroncelli S, Villani P, Cusato M, Cerioli A, De Martino M, Mastroiacovo P, Parazzini F, Vella S., Floridia M, Masuelli G, Meloni A, Cetin I, Tamburrini E, Cavaliere AF, Dalzero S, Sansone M, Alberico S, Guerra B, Spinillo A, Chiadò Fiorio Tin M, Ravizza M, and Mori F, Ortolani P, Dalle Nogare ER, Di Lorenzo F, Sterrantino G, Meli M, Polemi S, Nocentini J, Baldini M, Montorzi G, Mazzetti M, Rogasi P, Borchi B, Vichi F, Del Pin B, Pinter E, Anzalone E, Marocco R, Mastroianni C, Mercurio VS, Carocci A, Grilli E, Maccabruni A, Zaramella M, Mariani B, Natalini Raponi G, Guaraldi G, Nardini G, Stentarelli C, Beghetto B, Degli Antoni AM, Molinari A, Crisalli MP, Donisi A, Piepoli M, Cerri V, Zuccotti G, Giacomet V, Coletto S, Di Nello F, Madia C, Placido G, Vivarelli A, Castelli P, Savalli F, Portelli V, Sabbatini F, Francisci D, Bernini L, Grossi P, Rizzi L, Maso G, Airoud M, Soppelsa G, Dedoni M, Cuboni C, Ortu F, Piano P, Citernesi A, Bordoni Vicini I, Luzi K, Roccio M, Vimercati A, Miccolis A, De Gennaro A, Cervi F, Simonazzi G, Margarito E, Capretti MG, Marsico C, Faldella G, Martinelli P, Agangi A, Capone A, Maruotti GM, Tibaldi C, Trentini L, Todros T, Frisina V, Brambilla T, Savasi V, Personeni C, Giaquinto C, Fiscon M, Rubino E, Bucceri A, Matrone R, Scaravelli G, Genovese O, Cafforio C, Pinnetti C, Liuzzi G, Tozzi V, Massetti P, Casadei AM, Cellini M, Castelli Gattinara G, Marconi AM, Sacchi V, Ierardi M, Polizzi C, Mattei A, Pirillo MF, Amici R, Galluzzo CM, Donnini S, Baroncelli S, Villani P, Cusato M, Cerioli A, De Martino M, Mastroiacovo P, Parazzini F, Vella S.
- Subjects
Infectious Disease Transmission ,Prenatal diagnosis ,HIV Infections ,0302 clinical medicine ,Birth defect ,Pregnancy ,Odds Ratio ,Vertical ,Medicine ,030212 general & internal medicine ,Pregnancy Complications, Infectious ,education.field_of_study ,Amniocentesi ,030219 obstetrics & reproductive medicine ,medicine.diagnostic_test ,Obstetrics ,Infectious ,Obstetrics and Gynecology ,Amniocentesis ,birth defects ,chorionic villus sampling ,HIV ,invasive testing ,mother-to child HIV transmission ,pregnancy ,prenatal diagnosis ,Birth defects ,Chorionic villus sampling ,Invasive testing ,Mother-to child HIV transmission ,Anti-Retroviral Agents ,Chorionic Villi Sampling ,Female ,Adult ,medicine.medical_specialty ,Prenatal diagnosi ,Population ,Settore MED/17 - MALATTIE INFETTIVE ,03 medical and health sciences ,Humans ,education ,Fetal Death ,Analysis of Variance ,Chi-Square Distribution ,business.industry ,Infectious Disease Transmission, Vertical ,Odds ratio ,medicine.disease ,Confidence interval ,Pregnancy Complications ,business ,Chi-squared distribution - Abstract
Objectives To assess in pregnant women with HIV the rates of amniocentesis and chorionic villus sampling (CVS), and the outcomes associated with such procedures. Design Observational study. Data from the Italian National Program on Surveillance on Antiretroviral Treatment in Pregnancy were used. Setting University and hospital clinics. Population Pregnant women with HIV. Methods Temporal trends were analysed by analysis of variance and by the Chi-square test for trend. Quantitative variables were compared by Student's t-test and categorical data by the Chi-square test, with odds ratios and 95% confidence intervals calculated. Main outcome measures Rate of invasive testing, intrauterine death, HIV transmission. Results Between 2001 and 2015, among 2065 pregnancies in women with HIV, 113 (5.5%) had invasive tests performed. The procedures were conducted under antiretroviral treatment in 99 cases (87.6%), with a significant increase over time in the proportion of tests performed under highly active antiretroviral therapy (HAART) (100% in 2011–2015). Three intrauterine deaths were observed (2.6%), and 14 pregnancies were terminated because of fetal anomalies. Among 96 live newborns, eight had no information available on HIV status. Among the remaining 88 cases with either amniocentesis (n = 75), CVS (n = 12), or both (n = 1), two HIV transmissions occurred (2.3%). No HIV transmission occurred among the women who were on HAART at the time of invasive testing, and none after 2005. Conclusions The findings reinforce the assumption that invasive prenatal testing does not increase the risk of HIV vertical transmission among pregnant women under suppressive antiretroviral treatment. Tweetable abstract No HIV transmission occurred among women who underwent amniocentesis or CVS under effective anti-HIV regimens.
- Published
- 2016
23. Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015
- Author
-
Floridia, M., Frisina, V. b., Ravizza, M., Marconi, A. M., Pinnetti, C., Cetin, I., Sansone, M., Molinari, A., Cervi, F., Meloni, A., Luzi, K., Masuelli, G., Tamburrini, E., Ensoli, B., Moroni, M., Lazzarin, A., Sagnelli, E., Antinori, A., Carosi, G., Marcotullio, S., Mazzotta, F., Vella, S., Ammassari, A., Antonucci, G., Andreoni, M., Angarano, G., Armignacco, O., Babudieri, S., Baldelli, F., Bini, T., Bonfanti, Bonora, P., Borderi, S., Bruno, M., Bucciardini, R., Castagna, R, Cattelan, A., Cauda, A. M., Cerioli, R., Chirianni, A., Cingolani, A., Cinque, A., D'Arminio, Monforte, Carli, De, Luca, De, Perri, Di, Pietro, Di, Hamad, El, Errico, I., Ferrazzi, M., Gabrielli, E., Galli, E., Giaquinto, M., Girardi, C., Gori, E., Grossi, A., Guaraldi, P., Liuzzi, G., Caputo, Lo, Maggiolo, S., Malena, F., Maserati, M., Mastroianni, R., Matteelli, C., Morrone, A., Murri, A., Mussini, R., Nasta, C., Oldrini, P., Oleari, M., Orlando, F., Palù, G., Pempinello, G., Perno, R., Prestileo, C., Pompa, T., Puoti, M. G., Puro, M., Rancilio, V., Rasi, L., Rizzardini, G., Savasi, G., Signorini, V. M., Sighinolfi, L., Stagnitta, L., Starace, M., Starnini, F., Sterrantino, G., Suter, G., Tambussi, F., Tavio, G., Torti, M., Tozzi, C., Trotta, V., Vaccher, M. P., Viganò, E., Visintini, A., Vullo, R., Zuccotti, V., Dell'Isola, G. V., Manfredini, S., Parisi, V., Pezzoli, S., M. C., Floridia, M, Frisina, V, Ravizza, M, Marconi, A, Pinnetti, C, Cetin, I, Sansone, M, Molinari, A, Cervi, F, Meloni, A, Luzi, K, Masuelli, G, Tamburrini, E, Ensoli, B, Moroni, M, Lazzarin, A, Sagnelli, E, Antinori, A, Carosi, G, Marcotullio, S, Mazzotta, F, Vella, S, Ammassari, A, Antonucci, G, Andreoni, M, Angarano, G, Armignacco, O, Babudieri, S, Baldelli, F, Bini, T, Bonfanti, P, Bonora, S, Borderi, M, Bruno, R, Bucciardini, R, Castagna, A, Cattelan, A, Cauda, R, Cerioli, A, Chirianni, A, Cingolani, A, Cinque, P, d'Arminio Monforte, A, De Carli, G, De Luca, A, Di Perri, G, Di Pietro, M, El Hamad, I, Errico, M, Ferrazzi, E, Gabrielli, E, Galli, M, Giaquinto, C, Girardi, E, Gori, A, Grossi, P, Guaraldi, G, Liuzzi, G, Lo Caputo, S, Maggiolo, F, Malena, M, Maserati, R, Mastroianni, C, Matteelli, A, Morrone, A, Murri, R, Mussini, C, Nasta, P, Oldrini, M, Oleari, F, Orlando, G, Palu, G, Pempinello, R, Perno, C, Prestileo, T, Pompa, M, Puoti, M, Puro, V, Rancilio, L, Rasi, G, Rizzardini, G, Savasi, V, Signorini, L, Sighinolfi, L, Stagnitta, M, Starace, F, Starnini, G, Sterrantino, G, Suter, F, Tambussi, G, Tavio, M, Torti, C, Tozzi, V, Trotta, M, Vaccher, E, Vigano, A, Visintini, R, Vullo, V, Zuccotti, G, Dell'Isola, S, Manfredini, V, Parisi, S, Pezzoli, M, Zona, S, Floridia, M., Frisina, V., Ravizza, M., Marconi, A. M., Pinnetti, C., Cetin, I., Sansone, M., Molinari, A., Cervi, F., Meloni, A., Luzi, K., Masuelli, G., Tamburrini, E., Ensoli, B., Moroni, M., Lazzarin, A., Sagnelli, E., Antinori, A., Carosi, G., Marcotullio, S., Mazzotta, F., Vella, S., Ammassari, A., Antonucci, G., Andreoni, M., Angarano, G., Armignacco, O., Babudieri, S., Baldelli, F., Bini, T., Bonfanti, P., Bonora, S., Borderi, M., Bruno, R., Bucciardini, R., Castagna, A., Cattelan, A. M., Cauda, R., Cerioli, A., Chirianni, A., Cingolani, A., Cinque, P., d'Arminio Monforte, A., De Carli, G., De Luca, A., Di Perri, G., Di Pietro, M., El Hamad, I., Errico, M., Ferrazzi, E., Gabrielli, E., Galli, M., Giaquinto, C., Girardi, E., Gori, A., Grossi, P., Guaraldi, G., Liuzzi, G., Lo Caputo, S., Maggiolo, F., Malena, M., Maserati, R., Mastroianni, C., Matteelli, A., Morrone, A., Murri, R., Mussini, C., Nasta, P., Oldrini, M., Oleari, F., Orlando, G., Palu, G., Pempinello, R., Perno, C. -F., Prestileo, T., Pompa, M. G., Puoti, M., Puro, V., Rancilio, L., Rasi, G., Rizzardini, G., Savasi, V. M., Signorini, L., Sighinolfi, L., Stagnitta, M., Starace, F., Starnini, G., Sterrantino, G., Suter, F., Tambussi, G., Tavio, M., Torti, C., Tozzi, V., Trotta, M. P., Vaccher, E., Vigano, A., Visintini, R., Vullo, V., Zuccotti, G. V., Dell'Isola, S., Manfredini, V., Parisi, S., Pezzoli, M. C., and Zona, S.
- Subjects
0301 basic medicine ,Male ,Infectious Disease Transmission ,HIV Infections ,Pre-Exposure Prophylaxi ,Miscarriage ,Cohort Studies ,Pre-exposure prophylaxis ,0302 clinical medicine ,Pregnancy ,Prevalence ,Medicine ,Vertical ,HIV Infection ,030212 general & internal medicine ,Pregnancy Complications, Infectious ,Treatment implementation ,Obstetrics ,Health Policy ,Medicine (all) ,Infectious ,Pregnancy Outcome ,Articles ,3. Good health ,Sexual Partner ,Sexual Partners ,Italy ,Serodiscordant ,Chemoprophylaxis ,Female ,Live birth ,Adolescent ,Adult ,Anti-HIV Agents ,Fertilization ,Humans ,Infectious Disease Transmission, Vertical ,Pre-Exposure Prophylaxis ,Cohort study ,Human ,medicine.medical_specialty ,03 medical and health sciences ,Environmental health ,business.industry ,Public Health, Environmental and Occupational Health ,Anti-HIV Agent ,medicine.disease ,030112 virology ,Pregnancy Complications ,Pregnancy Complications, Infectiou ,Cohort Studie ,business - Abstract
Background The current global and national indications for antiretroviral treatment (ART, usually triple combination therapy) in adolescent and adults, including pregnant women, recommend early ART before immunologic decline, pre-exposure chemoprophylaxis (PrEP), and treatment of HIV-negative partners in serodiscordant couples. There is limited information on the implementation of these recommendations among pregnant women with HIV and their partners. Methods The present analysis was performed in 2016, using data from clinical records of pregnant women with HIV, followed between 2001 and 2015 at hospital or university clinics within a large, nationally representative Italian cohort study. The study period was divided in three intervals of five years each (2001-2005, 2006-2010, 2011-2015), and the analysis evaluated temporal trends in rates of HIV diagnosis in pregnancy, maternal antiretroviral treatment at conception, prevalence of HIV infection among partners of pregnant women with HIV, and proportion of seronegative and seropositive male partners receiving antiretroviral treatment. Results The analysis included 2755 pregnancies in women with HIV. During the three time intervals considered the rate of HIV diagnosis in pregnancy (overall 23.3%), and the distribution of HIV status among male partners (overall 48.7% HIV- negative, 28.6% HIV-positive and 22.8% unknown) remained substantially unchanged. Significant increases were observed in the proportion of women with HIV diagnosed before pregnancy who were on antiretroviral treatment at conception (from 62.0% in 2001-2005 to 81.3% in 2011-2015, P < 0.001), and in the proportion of HIV-positive partners on antiretroviral treatment (from 73.3% in 2001-2005 to 95.8% in 2011-2015, P = 0.002). Antiretroviral treatment was administered in 99.1% of the pregnancies that did not end early because of miscarriage, termination, or intrauterine death, and in 75.3% of those not ending in a live birth. No implementation of antiretroviral treatment was introduced among male HIV-negative partners. Conclusions The results suggest good implementation of antiretroviral treatment among HIV-positive women and their HIV-positive partners, but no implementation, even in recent years, of Pre-Exposure Prophylaxis (PrEP) among uninfected male partners. Further studies should assess the determinants of this occurrence and clarify the attitudes and the potential barriers to PrEP use.
- Published
- 2017
24. Declining HCV seroprevalence in pregnant women with HIV
- Author
-
FLORIDIA, M., TAMBURRINI, E., ANZIDEI, G., TIBALDI, C., MUGGIASCA, M. L., GUARALDI, G., FISCON, M., VIMERCATI, A., MARTINELLI, P., DONISI, A., DALZERO, S., and RAVIZZA, M.
- Published
- 2010
25. CD4/CD8 ratio in pregnant women with HIV and its association with pregnancy outcome: data from a national study in Italy.
- Author
-
Floridia, Marco, Pinnetti, Carmela, Masuelli, Giulia, Spinillo, Arsenio, Savasi, Valeria M., Liuzzi, Giuseppina, Degli Antoni, Anna M., Sansone, Matilde, Guaraldi, Giovanni, Dalzero, Serena, Maso, Gianpaolo, Francisci, Daniela, Sterrantino, Gaetana, Ravizza, Marina, Tamburrini, Enrica, The Italian Group on Surveillance of Antiretroviral Treatment in Pregnancy, Floridia, M., Ravizza, M., Tamburrini, E., and Di Lorenzo, F.
- Subjects
RNA analysis ,HIV infections ,STATISTICS ,PREMATURE infants ,CONFIDENCE intervals ,FIRST trimester of pregnancy ,THIRD trimester of pregnancy ,MULTIVARIATE analysis ,PREGNANT women ,PREGNANCY outcomes ,HIGHLY active antiretroviral therapy ,LOW birth weight ,RISK assessment ,DESCRIPTIVE statistics ,T cells ,ODDS ratio - Abstract
Purpose: To evaluate associations between CD4/CD8 ratio and pregnancy outcomes in women with HIV. Methods: We evaluated, in a national study of pregnant women with HIV receiving antiretroviral treatment (ART), values of CD4/CD8 ratio at entry in pregnancy, changes between first and third trimester, and possible associations with preterm delivery, low birthweight, and HIV-RNA < 50 copies/ml at third trimester in univariate and multivariate analyses. Results: Among 934 women, 536 (57.4%) were already on ART at conception. CD4/CD8 ratio (baseline value 0.570) increased significantly between the first and third trimesters, particularly in women who started ART in pregnancy (+ 0.163, vs. + 0.036 in women already on treatment). The rate of CD4/CD8 ratio normalization, defined by achieving a ratio ≥ 1 at the third trimester, was 13.2%. In multivariable analyses, women who entered pregnancy with a CD4/CD8 ratio < 0.3, compared to women with ratio ≥ 1, were almost four-times less likely to have third-trimester HIV-RNA < 50 copies/ml (AOR 0.258, 95%CI 0.111–0.601), and more than twice as likely to have preterm delivery (AOR 2.379, 95%CI 1.082–5.232). For preterm delivery, also a baseline CD4/CD8 ratio between 0.3 and 0.45 was significantly associated with an increased risk (AOR: 3.415, 95%CI 1.690–6.900). Conclusion: We described for the first time independent associations of low CD4/CD8 ratio with preterm delivery and HIV-RNA suppression. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index
- Author
-
Shi, Yuan, Thompson, Jennifer, Walker, A Sarah, Paton, Nicholas I, Cheung, Yin Bun, Agweng, E, Awio, P, Bakeinyaga, G, Isabirye, C, Kabuga, U, Kasuswa, S, Katuramu, M, Kityo, C, Kiweewa, F, Kyomugisha, H, Lutalo, E, Mugyenyi, P, Mulima, D, Musana, H, Musitwa, G, Musiime, V, Ndigendawan, M, Namata, H, Nkalubo, J, Labejja, P Ocitti, Okello, P, Olal, P, Pimundu, G, Segonga, P, Ssali, F, Tamale, Z, Tumukunde, D, Namala, W, Byaruhanga, R, Kayiwa, J, Tukamushaba, J, Abunyang, S, Eram, D, Denis, O, Lwalanda, R, Mugarura, L, Namusanje, J, Nankya, I, Ndashimye, E, Nabulime, E, Senfuma, O, Bihabwa, G, Buluma, E, Easterbrook, P, Elbireer, A, Kambugu, A, Kamya, D, Katwere, M, Kiggundu, R, Komujuni, C, Laker, E, Lubwama, E, Mambule, I, Matovu, J, Nakajubi, A, Nakku, J, Nalumenya, R, Namuyimbwa, L, Semitala, F, Wandera, B, Wanyama, J, Mugerwa, H, Lugemwa, A, Ninsiima, E, Ssenkindu, T, Mwebe, S, Atwine, L, William, H, Katemba, C, Acaku, M, Ssebutinde, P, Kitizo, H, Kukundakwe, J, Naluguza, M, Ssegawa, K, Namayanja, Nsibuka, F, Tuhirirwe, P, Fortunate, M, Acen, J, Achidri, J, Amone, A, Chamai, M, Ditai, J, Kemigisa, M, Kiconco, M, Matama, C, Mbanza, D, Nambaziira, F, Odoi, M Owor, Rweyora, A, Tumwebaze, G, Kalanzi, H, Katabaazi, J, Kiyingi, A, Mbidde, M, Mugenyi, M, Mwebaze, R, Okong, P, Senoga, I, Abwola, M, Baliruno, D, Bwomezi, J, Kasede, A, Mudoola, M, Namisi, R, Ssennono, F, Tuhirwe, S, Abongomera, G, Amone, G, Abach, J, Aciro, I, Arach, B, Kidega, P, Omongin, J, Ocung, E, Odong, W, Philliam, A, Alima, H, Ahimbisibwe, B, Atuhaire, E, Atukunda, F, Bekusike, G, Bulegyeya, A, Kahatano, D, Kamukama, S, Kyoshabire, J, Nassali, A, Mbonye, A, Naturinda, TM, Ndukukire, Nshabohurira, A, Ntawiha, H, Rogers, A, Tibyasa, M, Kiirya, S, Atwongyeire, D, Nankya, A, Draleku, C, Nakiboneka, D, Odoch, D, Lakidi, L, Ruganda, R, Abiriga, R, Mulindwa, M, Balmoi, F, Kafuma, S, Moriku, E, Hakim, J, Reid, A, Chidziva, E, Musoro, G, Warambwa, C, Tinago, G, Mutsai, S, Phiri, M, Mudzingwa, S, Bafana, T, Masore, V, Moyo, C, Nhema, R, Chitongo, S, Heyderman, Robert, Kabanga, Lucky, Kaunda, Symon, Kudzala, Aubrey, Lifa, Linly, Mallewa, Jane, Moore, Mike, Mtali, Chrissie, Musowa, George, Mwimaniwa, Grace, Sikwese, Rosemary, van Oosterhout, Joep, Ziwoya, Milton, Chimbaka, H, Chitete, B, Kamanga, S, Kayinga, T, Makwakwa, E, Mbiya, R, Mlenga, M, Mphande, T, Mtika, C, Mushani, G, Ndhlovu, O, Ngonga, M, Nkhana, I, Nyirenda, R, Cheruiyot, P, Kwobah, C, Ekiru, W Lokitala, Mokaya, M, Mudogo, A, Nzioka, A, Siika, A, Tanui, M, Wachira, S, Wools-Kaloustian, K, Alipalli, P, Chikatula, E, Kipaila, J, Kunda, I, Lakhi, S, Malama, J, Mufwambi, W, Mulenga, L, Mwaba, P, Mwamba, E, Mweemba, A, Namfukwe, M, Kerukadho, E, Ngwatu, B, Birungi, J, Paton, N, Boles, J, Burke, A, Castle, L, Ghuman, S, Kendall, L, Hoppe, A, Tebbs, S, Thomason, M, Thompson, J, Walker, S, Whittle, J, Wilkes, H, Young, N, Kapuya, C, Kyomuhendo, F, Kyakundi, D, Mkandawire, N, Mulambo, S, Senyonjo, S, Angus, B, Arenas-Pinto, A, Palfreeman, A, Post, F, Ishola, D, Arribas, J, Colebunders, R, Floridia, M, Giuliano, M, Mallon, P, Walsh, P, De Rosa, M, Rinaldi, E, Weller, I, Gilks, C, Kangewende, A, Luyirika, E, Miiro, F, Mwamba, P, Ojoo, S, Phiri, S, van Oosterhout, J, Wapakabulo, A, Peto, T, French, N, Matenga, J, Cloherty, G, van Wyk, J, Norton, M, Lehrman, S, Lamba, P, Malik, K, Rooney, J, Snowden, W, Villacian, J, Team, EARNEST Trial, UAM. Departamento de Medicina, and Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)
- Subjects
Adult ,Male ,Mean squared error ,Medicina ,Intraclass correlation ,HIV Infections ,lcsh:Computer applications to medicine. Medical informatics ,Standard deviation ,03 medical and health sciences ,0302 clinical medicine ,EQ-5D ,Outcome Assessment, Health Care ,Statistics ,Covariate ,Humans ,030212 general & internal medicine ,Least-Squares Analysis ,Africa South of the Sahara ,Health utility ,Mathematics ,Medical outcomes study HIV health survey ,Research ,030503 health policy & services ,1. No poverty ,Public Health, Environmental and Occupational Health ,General Medicine ,Health Surveys ,Regression ,3. Good health ,Mapping ,Ordinary least squares ,Quality of Life ,lcsh:R858-859.7 ,Female ,0305 other medical science ,Body mass index - Abstract
Background: Mapping of health-related quality-of-life measures to health utility values can facilitate cost-utility evaluation. Regression-based methods tend to lead to shrinkage of variance. This study aims to map the Medical Outcomes Study HIV Health Survey (MOS-HIV) to EuroQoL 5 Dimensions (EQ-5D-3 L) utility index, and to characterize the performance of three mapping methods, including ordinary least squares (OLS), equi-percentile method (EPM), and a recently proposed method called Mean Rank Method (MRM). Methods: This is a secondary analysis of data from a randomized HIV treatment trial. Baseline data from 421 participants were used to develop mapping functions. Follow-up data from 236 participants was used to validate the mapping functions. Results: In the training dataset, MRM and OLS, but not EPM, reproduced the observed mean utility (0.731). MRM, OLS and EPM under-estimated the standard deviation by 0.3, 26.6 and 1.7%, respectively. MRM had the lowest mean absolute error (0.143) and highest intraclass correlation coefficient (0.723) with the observed utility values, whereas OLS had the lowest mean squared error (0.038) and highest R-squared (0.542). Regressing the MRM- and OLS-mapped utility values upon body mass index and log-viral load gave covariate associations comparable to those estimated from the observed utility data (all P > 0.10). EPM did not achieve this property. Findings from the validation data were similar. Conclusions: Functions are available for mapping the MOS-HIV to the EQ-5D-3 L utility values. MRM and OLS were comparable in terms of agreement with the observed utility values at the individual level. MRM had better performance at the group level in terms of describing the utility distribution. Trial registration: NCT00988039. Registered 30 September 2009., The EARNEST trial was funded by the European and Developing Countries Clinical Trials Partnership (EDCTP, Grant Code: IP.2007.33011.003) with contributions from the Medical Research Council, UK; Institito de Salud Carlos III, Spain (Grant A107/90015); Irish Aid, Ireland; Swedish International Development Cooperation Agency (SIDA), Sweden; Instituto Superiore di Sanita (ISS), Italy; The World Health Organisation; and Merck, USA. Substantive in-kind contributions were made by the Medical Research Council Clinical Trials Unit, UK [MC_UU_12023/23], CINECA, Bologna, Italy, Janssen Diagnostics, Beerse, Belgium; GSK/ViiV Healthcare Ltd., UK; Abbott Laboratories, USA. Trial medication was donated by AbbVie, Merck, Pfizer, GSK and Gilead. The Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi
- Published
- 2019
27. Pregnancy outcomes and antiretroviral treatment in a national cohort of pregnant women with HIV: overall rates and differences according to nationality
- Author
-
Floridia, M, Tamburrini, E, Bucceri, A, Tibaldi, C, Anzidei, G, Guaraldi, G, Meloni, A, Guerra, B, Ferrazzi, E, Molinari, A, Pinnetti, C, Salerio, B, and Ravizza, M
- Published
- 2007
28. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women
- Author
-
Villani, P., Floridia, M., Pirillo, M. F., Cusato, M., Tamburrini, E., Cavaliere, A. F., Guaraldi, G., Vanzini, C., Molinari, A., Antoni, A. degli, and Regazzi, M.
- Published
- 2006
29. Lipid Profile During Pregnancy in HIV-Infected Women
- Author
-
Floridia, M., Tamburrini, E., Ravizza, M., Tibaldi, C., Ravagni Probizer, M. F., Anzidei, G., Sansone, M., Mori, F., Rubino, E., Meli, M., Dalzero, S., and Guaraldi, G.
- Published
- 2006
30. Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels ( < 50 cells/μL)
- Author
-
Floridia, M, Bucciardini, R, Fragola, V, Galluzzo, C M, Giannini, G, Pirillo, M F, Amici, R, Andreotti, M, Ricciardulli, D, Tomino, C, and Vella, S
- Published
- 2004
31. HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/μL): an analysis of 338 clinical events from a randomized clinical trial
- Author
-
Floridia, M, Fragola, V, Galluzzo, C M, Giannini, G, Pirillo, M F, Andreotti, M, Tomino, C, and Vella, S
- Published
- 2002
32. Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women with Hiv: Laboratory and Clinical Outcomes in an Observational National Study
- Author
-
Floridia, M., Pinnetti, C., Ravizza, M., Masuelli, G., Personeni, C., Sansone, M., Antoni, A. D., Guaraldi, G., Spinillo, A., Tassis, B., Dalzero, S., Liuzzi, G., Tamburrini, E., Di Lorenzo, F., Sterrantino, G., Meli, M., Campolmi, I., Vichi, F., Del Pin, B., Marocco, R., Mastroianni, C., Mercurio, V. S., Maccabruni, A., Zaramella, M., Mariani, B., Nardini, G., Stentarelli, C., Beghetto, B., Degli Antoni, A. M., Molinari, A., Crisalli, M. P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Coletto, S., Di Nello, F., Madia, C., Placido, G., Milini, P., Savalli, F., Portelli, V., Sabbatini, F., Francisci, D., Papalini, C., Bernini, L., Grossi, P., Rizzi, L., Bernardon, M., Maso, G., Rizzante, E., Belcaro, C., Meloni, A., Dedoni, M., Ortu, F., Piano, P., Citernesi, A., Vicini, I. B., Luzi, K., Roccio, M., Vimercati, A., Miccolis, A., De Gennaro, A., Guerra, B., Cervi, F., Simonazzi, G., Margarito, E., Capretti, M. G., Marsico, C., Faldella, G., Martinelli, P., Agangi, A., Capone, A., Maruotti, G. M., Tibaldi, C., Trentini, L., Todros, T., Frisina, V., Cetin, I., Brambilla, T., Savasi, V., Giaquinto, C., Fiscon, M., Rubino, E., Franceschetti, L., Badolato, R., Tiso, G. C., Genovese, O., Cafforio, C., Casadei, A. M., Cavaliere, A. F., Cellini, M., Marconi, A. M., Sacchi, V., Ierardi, M., Polizzi, C., Mattei, A., Pirillo, M. F., Amici, R., Galluzzo, C. M., Donnini, S., and Baroncelli, S.
- Subjects
0301 basic medicine ,HIV Infections ,Hemoglobins ,0302 clinical medicine ,Abacavir ,Anemia ,Cholesterol ,Emtricitabine ,HIV-RNA ,Lamivudine ,Low birthweight ,Pregnancy ,Preterm delivery ,Tenofovir ,immune system diseases ,Antiretroviral Therapy, Highly Active ,Pharmacology (medical) ,030212 general & internal medicine ,Pregnancy Outcome ,virus diseases ,Lipoproteins, LDL ,Drug Combinations ,Infectious Diseases ,Hypertension ,RNA, Viral ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Anti-HIV Agents ,Pregnancy Trimester, Third ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,AIDS-Associated Nephropathy ,Cesarean Section ,business.industry ,Abacavir/Lamivudine ,medicine.disease ,030112 virology ,Dideoxynucleosides ,CD4 Lymphocyte Count ,Pregnancy Complications ,HIV-1 ,Observational study ,business - Abstract
Abacavir-lamivudine (ABC/3TC) and tenofovir-emtricitabine (TDF/FTC) represent in the guidelines of several countries, including Italy and United States, the preferred nucleoside/nucleotide backbones of antiretroviral regimens. We assessed their profile in pregnancy using data from a national observational study.Laboratory measures (CD4, HIV-RNA, lipid profile, glucose, hemoglobin, and alanine transferase) and pregnancy outcomes (preterm delivery, low birthweight, nonelective cesarean section, birthweight Z-score, congenital defects, HIV transmission, maternal weight gain, and pregnancy complications) were compared after prenatal exposure to ABC/3TC or TDF/FTC.The study evaluated 913 pregnancies (ABC/3TC: 252; TDF/FTC: 661). At entry in pregnancy, women on TDF/FTC were older (33.6 vs. 32.4 years, P = 0.005), less frequently on treatment (66.9% vs. 80.2%, P0.001), and had lower CD4 counts (475/mm vs. 533/mm, P = 0.003) and higher plasma HIV-RNA levels (2.48 vs. 2.22 log10 copies/mL, P = 0.003). Women on ABC/3TC had more commonly hypertension/nephropathy (5.2% vs. 2.0%, P = 0.013). No major differences were observed in the main pregnancy outcomes and in rates of undetectable HIV-RNA at third trimester. In a subgroup analysis that evaluated at third trimester only cases with regular 3-drug treatment during pregnancy, women on TDF/FTC had lower hemoglobin levels (median: 11.1 vs. 11.8 g/dL, P = 0.002) and women on ABC/3TC had higher levels of total cholesterol (median: 230 vs. 216 mg/dL, P = 0.023) and low-density lipoprotein-cholesterol (133 vs. 111 mg/dL, P = 0.030).In this study, use of TDF/FTC and ABC/3TC in pregnancy was associated with similar pregnancy outcomes and with some differences in laboratory measures that might guide physicians' prescriptions in mothers with hematologic or metabolic risk factors.
- Published
- 2018
33. Weight Gain during Pregnancy in Women with HIV Receiving Different Antiretroviral Regimens
- Author
-
Floridia, Marco, Masuelli, Giulia, Tassis, Beatrice, Franceschetti, Laura, Savasi, Valeria Maria, Spinillo, Arsenio, Tamburrini, Enrica, Guaraldi, Giovanni, Dalzero, Serena, Sansone, Matilde, Chiodo, Antonella, Antoni, Anna Maria Degli, Pinnetti, Carmela, Liuzzi, Giuseppina, Ravizza, Marina, Floridia, M., Ravizza, M., Tamburrini, E., Ravizza, M., Tamburrini, E., Lorenzo, F. Di, Sterrantino, G., Meli, M., Campolmi, I., Vichi, F., Pin, B. Del, Marocco, R., Mastroianni, C., Mercurio, V.S., Zanaboni, D., Guaraldi, G., Nardini, G., Stentarelli, C., Beghetto, B., Antoni, A.M. Degli, Molinari, A., Crisalli, M.P., Donisi, A., Ruggieri, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Paradiso, L., Forlanini, F., Longoni, E., Placido, G., Milini, P., Savalli, F., Portelli, V., Sabbatini, F., Francisci, D., Papalini, C., Bernini, L., Grossi, P., Rizzi, L., Maso, G., Bernardon, M., Bussolaro, S., Pietà, I. Della, Sorz, A., Meloni, A., Chiodo, A., Dedoni, M., Ortu, F., Piano, P., Citernesi, A., Vicini, I. Bordoni, Luzi, K., Spinillo, A., Roccio, M., Vimercati, A., Calabretti, D., Gigante, S., Guerra, B., Cervi, F., Simonazzi, G., Margarito, E., Capretti, M.G., Marsico, C., Faldella, G., Sansone, M., Martinelli, P., Agangi, A., Capone, A., Maruotti, G.M., Tibaldi, C., Trentini, L., Todros, T., Masuelli, G., Frisina, V., Savasi, V., Cardellicchio, E., Giaquinto, C., Fiscon, M., Rubino, E., Franceschetti, L., Badolato, R., Forleo, M.A., Tassis, B., Ruggiero, M., Genovese, O., Cafforio, C., Pinnetti, C., Liuzzi, G., Casadei, A.M., Cavaliere, A.F., Cellini, M., Marconi, A.M., Dalzero, S., Ierardi, M., Simonetti, S.C., Alfieri, N., Agrati, S., Polizzi, C., Mattei, A., Pirillo, M.F., Amici, R., Galluzzo, C.M., Donnini, S., Baroncelli, S., Floridia, M., Cerioli, A., Martino, M. De, Parazzini, F., Tamburrini, E., Vella, S., Martinelli, P., and Ravizza, M.
- Abstract
Background No published studies have evaluated in pregnant women with HIV weight gain with different antiretroviral drug classes.Methods Data from a national cohort study were used. We compared absolute weight gain and occurrence of excessive weight gain in women with HIV who received during pregnancy integrase inhibitors (INSTI), protease inhibitors (PI), or non-nucleoside reverse transcriptase inhibitors (NNRTI). Excessive weight gain was defined according to the Institute of Medicine recommendations. Possible predictors of weight gain were assessed using univariate and multivariate analyses.Results Among 273 cases (PI: 191, NNRTI: 43, INSTI: 39), the mean weight increase was 11.3 kg, and 25.4% of the mothers had an excessive weight increase. No significant differences were found among the three treatment groups for absolute weight increase, occurrence of excessive weight gain, infant birthweight, and other pregnancy and laboratory outcomes. The comparisons of individual drugs, although based on a limited number of cases, suggested no major differences. A significant positive correlation was found between weight gain and CD4+T-cell increase during pregnancy. In multivariate analyses, drug class and nucleoside backbone were not associated with absolute or excessive weight increase. Excessive weight increase was significantly associated with week of delivery (adjusted odds ratio: 1.74, 95% CI 1.15, 2.63), obesity (5.21, 95% CI 1.85, 14.64), overweight (7.95, 95% CI 3.26, 19.39), recent substance use (5.96, 95% CI 1.13, 31.40) and fasting 2nd trimester hyperglycaemia (3.94, 95% CI 1.14, 13.65).Conclusions No significant differences in absolute weight change or occurrence of excessive weight gain were found among women with HIV who received during pregnancy different classes of antiretroviral drugs.
- Published
- 2020
- Full Text
- View/download PDF
34. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease
- Author
-
Floridia, M., Bucciardini, R., Ricciardulli, D., Fragola, V., Pirillo, M.F., Weimer, L.E., Tomino, C., Giannini, G., Galluzzo, C.M., Andreotti, M., Cargnel, A., Alberici, F., De Rienzo, B., Leoncini, F., Fiaccadori, F., Francisci, D., Grillone, W., Ortona, L., Piazza, M., Scalzini, A., Nigra, E., Tumietto, F., and Vella, S.
- Subjects
HIV infection -- Drug therapy ,Zidovudine -- Evaluation ,Didanosine -- Evaluation ,Health - Abstract
Triple combination therapy with nevirapine, zidovudine and didanosine appears to be effective even in patients with advanced HIV infection. Nevirapine belongs to a class of drugs called nonnucleoside reverse transcriptase inhibitors. Researchers randomly assigned 68 patients with advanced HIV infection to take nevirapine, zidovudine and didanosine or zidovudine and didanosine. None of the patients had received AIDS drugs in the past. Those receiving triple therapy had greater reductions in viral levels and greater increases in CD4 T cell counts comparing to those taking two drugs.
- Published
- 1999
35. Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity
- Author
-
Ortu F, Weimer LE, Floridia M, and Manconi PE
- Subjects
HIV/HCV ,antiretroviral treatment ,raltegravir ,tenofovir ,emtricitabine ,chronic active hepatitis ,Medicine - Abstract
Abstract Background in HIV-infected patients with HCV-related chronic hepatitis, liver impairment and drug toxicity may substantially reduce the number of possible therapeutic options. Case Description we here describe the case of an HCV-HIV coinfected woman who had repeated severe episodes of drug-related liver toxicity with indinavir, saquinavir, fosamprenavir, and darunavir, with minimal further therapeutic options left in this class. Previous treatment-limiting side effects with efavirenz and nevirapine also precluded use of non-nucleoside reverse transcriptase inhibitors. Introduction of an integrase-inhibitor regimen based on raltegravir, tenofovir, and emtricitabine allowed a prompt achievement of undetectable viral load and a substantial rise of CD4 count to high levels, with no subsequent episodes of hepatic toxicity, and no other side effects. Conclusions given the relatively common prevalence of HCV-related chronic hepatitis among people with HIV, raltegravir might represent an important alternative option for a substantial number of patients who cannot be treated with protease inhibitors or NNRTI because of drug-related hepatic toxicity.
- Published
- 2010
- Full Text
- View/download PDF
36. Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection
- Author
-
Weimer, L. E., Fragola, V., Floridia, M., Guaraldi, G., Ladisa, N., Francisci, D., Bellagamba, R., Degli Antoni, A., Parruti, G., Giacometti, A., Manconi, P. E., Vivarelli, A., D'Ettorre, G., Mura, M. S., Cicalini, S., Preziosi, R., Sighinolfi, L., Verucchi, G., Libertone, R., Tavio, M., Sarmati, L., Bucciardini, R., Angarano, G., Volpe, A., Vullo, V., Ceccarelli, G., Andreoni, M., Delle Rose, D., Tozzi, V., Narciso, P., Petrosillo, N., Pucillo, V., Tommasi, C., Segala, D., Armignacco, O., Ferrari, C., Cavalli, A., Sozio, F., Cosentino, L., Ortu, F., Viale, P., Tedeschi, S., Manfredi, R., Mannazzu, M., Cattari, G., Del Gobbo, R., Mataloni Paggi, A., Cirioni, O., Marchionni, E., Silvestri, C., Brescini, L., Sebastianelli, S., Baldelli, F., Mercuri, A., Bastianelli, S., Nardini, G., Massella, M., Baroncelli, S., Galluzzo, C. M., Pirillo, M. F., Mancini, M. G., Amici, R., Cara, A., Bona, R., Leone, P., Filati, P., Franco, M., Donnini, S., Weimer LE, Fragola V, Floridia M, Guaraldi G, Ladisa N, Francisci D, Bellagamba R, Degli Antoni A, Parruti G, Giacometti A, Manconi PE, Vivarelli A, D'Ettorre G, Mura MS, Cicalini S, Preziosi R, Sighinolfi L, Verucchi G, Libertone R, Tavio M, Sarmati L, and Bucciardini R on behalf of the ISS-NIA Study Group
- Subjects
Male ,HAART ,maraviroc ,viruses ,HIV Infections ,darunavir ,hiv-1 ,Hepacivirus ,medicine.disease_cause ,Cohort Studies ,hiv resistance ,Pharmacology (medical) ,cd4 response ,Original Research ,Aged, 80 and over ,Coinfection ,virus diseases ,Hepatitis C ,Middle Aged ,Hepatitis B ,viral load ,Treatment Outcome ,integrase inhibitors ,Infectious Diseases ,hbv ,Female ,liver disease ,Viral hepatitis ,Viral load ,medicine.drug ,Adult ,Microbiology (medical) ,Hepatitis B virus ,Hepatitis C virus ,HIV infection ,HCV infection ,HBV infection ,antiretroviral therapy ,viral hepatitis ,etravirine ,hcv ,NO ,Young Adult ,Antiretroviral therapy ,CD4 response ,Darunavir ,Etravirine ,HBV ,HCV ,HIV resistance ,HIV-1 ,Integrase inhibitors ,Liver disease ,Maraviroc ,medicine ,Humans ,Aged ,Salvage Therapy ,Pharmacology ,business.industry ,Raltegravir ,HIV ,medicine.disease ,Virology ,digestive system diseases ,Immunology ,business ,Follow-Up Studies - Abstract
OBJECTIVES: To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroimmunological response to raltegravir-based salvage regimens that also include new HIV inhibitors such as maraviroc, darunavir and etravirine. METHODS: We used data from a national observational study of patients starting raltegravir-based regimens to compare virological suppression and CD4 cell change from baseline in patients with and without concomitant HBV or HCV infection. RESULTS: Overall, 275 patients (107 coinfected and 168 non-coinfected) were evaluated. Coinfected patients were more commonly former intravenous drug users and had a longer history of HIV infection and higher baseline aminotransferase levels. Both HIV-RNA and CD4 response were similar in the two groups. Mean time to first HIV-RNA copy number
- Published
- 2012
37. Results of a randomized multicenter study (ISS 902) for the comparative evaluation of AZT and DDI in previously untreated patients with mildly symptomatic HIV disease
- Author
-
Stefano, Vella, Floridia, M., Seeber, A., Tomino, C., Sebastiani, G., Fragola, V., Weimer, L. E., and Ricciardulli, D.
- Published
- 1994
38. Pregnant with HIV before age 25: Data from a large national study in Italy, 2001-2016
- Author
-
Floridia, M., Masuelli, G., Tamburrini, E., Cetin, I., Liuzzi, G., Martinelli, Paolo, Guaraldi, G., Spinillo, A., Vimercati, A., Maso, G., Pinnetti, C., Frisina, V., Dalzero, S., Ravizza, M., Di Lorenzo, F., Sterrantino, G., Meli, M., Campolmi, I., Vichi, F., Del Pin, B., Marocco, R., Mastroianni, C., Mercurio, V. S., Maccabruni, A., Zaramella, M., Mariani, Bianca, Nardini, G., Stentarelli, C., Beghetto, B., Antoni, A. M. Degli, Molinari, A., Crisalli, M. P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Coletto, S., Di Nello, F., Madia, C., Placido, G., Milini, P., Savalli, F., Portelli, V., Sabbatini, F., Francisci, D., Angeli, G., Bernini, L., Grossi, P., Rizzi, L., Bernardon, M., Rizzante, E., Belcaro, C., Meloni, Antonio, Dedoni, M., Ortu, F., Piano, Pierluigi, Citernesi, A., Vicini, I. Bordoni, Luzi, K., Roccio, M., Miccolis, A., De Gennaro, A., Guerra, B., Cervi, Filippo, Simonazzi, G., Margarito, E., Capretti, M. G., Marsico, C., Faldella, G., Sansone, M., Agangi, A., Capone, A., Maruotti, G. M., Tibaldi, C., Trentini, L., Todros, T., Brambilla, T., Savasi, V., Personeni, C., Giaquinto, C., Fiscon, M., Rubino, E., Franceschetti, L., Tassis, B., Genovese, O., Cafforio, C., Casadei, A. M., Cavaliere, A. F., Cellini, Matteo, Marconi, A. M., Sacchi, V., Ierardi, M., Polizzi, C., Mattei, A., Pirillo, M. F., Amici, R., Galluzzo, C. M., Donnini, S., Baroncelli, S., Cerioli, A., DE MARTINO, MARIA CRISTINA, Parazzini, F., and Vella, S.
- Subjects
Antiretroviral treatment ,HIV diagnosis ,HIV testing ,pregnancy ,women's health ,medicine.medical_specialty ,Pediatrics ,Longitudinal study ,Adolescent ,Epidemiology ,Short Report ,HIV Infections ,Cohort Studies ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Pregnancy ,medicine ,Odds Ratio ,Humans ,030212 general & internal medicine ,Young adult ,030219 obstetrics & reproductive medicine ,business.industry ,Odds ratio ,medicine.disease ,Female ,Italy ,Infectious Diseases ,Confidence interval ,Family planning ,business ,Cohort study - Abstract
SUMMARYYoung pregnant women with HIV may be at significant risk of unplanned pregnancy, lower treatment coverage, and other adverse pregnancy outcomes. In a large cohort of pregnant women with HIV in Italy, among 2979 pregnancies followed in 2001–2016, 9·0% were in women P< 0·001). Younger women had a lower rate of planned pregnancy (23·2%vs.37·7%, odds ratio (OR) 0·50, 95% confidence interval (CI) 0·36–0·69), were more frequently diagnosed with HIV in pregnancy (46·5%vs.20·9%, OR 3·29, 95% CI 2·54–4·25), and, if already diagnosed with HIV before pregnancy, were less frequently on antiretroviral treatment at conception (vs.99·3%), with no differences in rate of HIV viral suppression at third trimester and adverse pregnancy outcomes. The data show that young women represent a growing proportion of pregnant women with HIV, and are significantly more likely to have unplanned pregnancy, undiagnosed HIV infection, and lower treatment coverage at conception. During pregnancy, antiretroviral treatment, HIV suppression, and pregnancy outcomes are similar compared with older women. Earlier intervention strategies may provide additional benefits in the quality of care for women with HIV.
- Published
- 2017
39. Tuberculosis case finding with combined rapid point of care assays (Xpert® MTB/RIF and LAM) in HIV-positive individuals starting antiretroviral treatment in Mozambique
- Author
-
Floridia, M, Ciccacci, F, Andreotti, M, Hassane, A, Sidumo, Z, Magid, N, Sotomane, H, David, M, Mutemba, E, Cebola, J, Mugunhe, R, Riccardi, F, Marazzi, M, Giuliano, M, Palombi, L, and Mancinelli, S
- Subjects
MTB/RIF ,Xpert® ,Settore MED/17 - Malattie Infettive ,Settore MED/42 - Igiene Generale e Applicata ,Africa ,HIV ,LAM ,Tuberculosis - Published
- 2017
40. Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment
- Author
-
Vella, Stefano, Galluzzo, M.C, Giannini, G, Pirillo, M.F, Andreotti, M, Tomino, C, Fragola, V, Bucciardini, R, Ricciardulli, D, Binelli, A, Weimer, L.E, and Floridia, M
- Published
- 2000
- Full Text
- View/download PDF
41. Pregnancy outcomes and cytomegalovirus DNAaemia in HIV-infected pregnant women with CMV
- Author
-
Ravizza, M., Tamburrini, E., Mori, F., Ortolani, P., dalle Nogare, E.R., Di Lorenzo, F., Sterrantino, G., Meli, M., Polemi, S., Nocentini, J., Baldini, M., Montorzi, G., Mazzetti, M., Rogasi, P., Borchi, B., Vichi, F., Del Pin, B., Pinter, E., Anzalone, E., Marocco, R., Mastroianni, C., Mercurio, V.S., Carocci, A., Grilli, E., Maccabruni, A., Zaramella, M., Mariani, B., Natalini Raponi, G., Guaraldi, G., Nardini, G., Stentarelli, C., Beghetto, B., Degli Antoni, A.M., Molinari, A., Crisalli, M.P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Coletto, S., Di Nello, F., Madia, C., Placido, G., Vivarelli, A., Castelli, P., Savalli, F., Portelli, V., Sabbatini, F., Francisci, D., Bernini, L., Grossi, P., Rizzi, L., Alberico, S., Maso, G., Airoud, M., Soppelsa, G., Meloni, A., Dedoni, M., Cuboni, C., Ortu, F., Piano, P., Citernesi, A., Bordoni Vicini, I., Luzi, K., Spinillo, A., Roccio, M., Vimercati, A., Miccolis, A., De Gennaro, A., Guerra, B., Cervi, F., Simonazzi, G., Margarito, E., Capretti, M.G., Marsico, C., Faldella, G., Sansone, M., Martinelli, P., Agangi, A., Capone, A., Maruotti, G.M., Tibaldi, C., Trentini, L., Todros, T., Masuelli, G., Frisina, V., Cetin, I., Brambilla, T., Savasi, V., Personeni, C., Giaquinto, C., Fiscon, M., Rubino, E., Bucceri, A., Matrone, R., Scaravelli, G., Genovese, O., Cafforio, C., Pinnetti, C., Liuzzi, G., Tozzi, V., Massetti, P., Casadei, A.M., Cavaliere, A.F., Cellini, M., Castelli Gattinara, G., Marconi, A.M., Dalzero, S., Sacchi, V., Ierardi, M., Polizzi, C., Mattei, A., Pirillo, M.F., Amici, R., Galluzzo, C.M., Donnini, S., Baroncelli, S., Floridia, M., Villani, P., Cusato, M., Cerioli, A., De Martino, M., Mastroiacovo, P., Parazzini, F., Vella, S., and Degli Antoni, A.
- Published
- 2016
- Full Text
- View/download PDF
42. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF
- Author
-
Orlando, S., primary, Triulzi, I., additional, Ciccacci, F., additional, Palla, I., additional, Palombi, L., additional, Marazzi, M. C., additional, Giuliano, M., additional, Floridia, M., additional, Mancinelli, S., additional, Mutemba, E., additional, and Turchetti, G., additional
- Published
- 2018
- Full Text
- View/download PDF
43. Body Mass Index and Weight Gain in Pregnant Women With HIV: A National Study in Italy
- Author
-
Floridia, M., Ravizza, M., Masuelli, G., Dalzero, S., Pinnetti, C., Cetin, I., Meloni, A., Spinillo, A., Rubino, E., Francisci, D., Tamburrini, E., Mori, F., Ortolani, P., Dalle Nogare, E. R., Di Lorenzo, F., Sterrantino, G., Meli, M., Polemi, S., Nocentini, J., Baldini, M., Montorzi, G., Mazzetti, M., Rogasi, P., Borchi, B., Vichi, F., Pinter, E., Anzalone, E., Marocco, R., Mastroianni, Claudio Maria, Mercurio, V. S., Carocci, A., Grilli, E., Maccabruni, A., Zaramella, M., Mariani, B., Natalini Raponi, G., Guaraldi, G., Luzi, K., Nardini, G., Stentarelli, C., Degli Antoni, A. M., Molinari, A., Crisalli, M. P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Fabiano, V., Placido, G., Vivarelli, A., Castelli, P., Savalli, F., Portelli, V., Sabbatini, F., Bernini, L., Alberico, S., Maso, G., Tropea, M., Dedoni, M., Cuboni, C., Ortu, F., Piano, P., Citernesi, A., Vicini, I., Roccio, M., Vimercati, A., Miccolis, A., Bassi, E., Guerra, B., Cervi, F., Puccetti, C., Murano, P., Contoli, M., Capretti, M. G., Marsico, C., Faldella, G., Sansone, M., Martinelli, P., Agangi, A., Tibaldi, C., Trentini, L., Todros, T., Garetto, S., Brambilla, T., Savasi, V., Crepaldi, A., Giaquinto, C., Fiscon, M., Rinaldi, R., Bucceri, A., Matrone, R., Scaravelli, G., Fundaro, C., Genovese, O., Cafforio, C., Liuzzi, G., Tozzi, V., Massetti, Anna Paola, Anceschi, M., Casadei, A. M., Cavaliere, A. F., Finelli, V., Cellini, M., Castelli Gattinara, G., Marconi, A. M., Sacchi, V., De Pirro, A., Polizzi, C., Mattei, A., Pirillo, M. F., Amici, R., Galluzzo, C. M., Donnini, S., Baroncelli, S., Villani, P., Cusato, M., Cerioli, A., De Martino, M., Mastroiacovo, P., Moroni, M., Parazzini, F., Vella, S., Floridia, M, Ravizza, M, Masuelli, G, Dalzero, S, Pinnetti, C, Cetin, I, Meloni, A, Spinillo, A, Rubino, E, Francisci, D, Tamburrini, E, Italian Group on Surveillance on Antiretroviral Treatment in, Pregnancy, Martinelli, Pasquale, Floridia M, Ravizza M, Masuelli G, Dalzero S, Pinnetti C, Cetin I, Meloni A, Spinillo A, Rubino E, Francisci D, Tamburrini E, Faldella G, Guerra B, and for the Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,antiretroviral therapy ,MEDLINE ,Human immunodeficiency virus (HIV) ,HIV Infections ,body mass index ,medicine.disease_cause ,Settore MED/17 - MALATTIE INFETTIVE ,Body Mass Index ,BMI ,weight gain ,HIV-1 ,Pregnancy ,Medicine ,Humans ,HIV infection ,pregnancy ,Pregnancy Complications, Infectious ,business.industry ,Obstetrics ,Cesarean Section ,Infectious ,Pregnancy Outcome ,HIV ,medicine.disease ,Pregnancy Complications ,Infectious Diseases ,Italy ,National study ,Female ,medicine.symptom ,business ,Weight gain ,Body mass index - Abstract
Although most of the women (69.4%) had a normal BMI at start of pregnancy, only 37% had an adequate weight gain during pregnancy. Inadequate body weight gain was more common (44.8%) than excessive weight gain (18.2%), but 40% of overweight women and 50% of obese women had an excessive weight gain in pregnancy, with about 9% of the women in these categories gaining >18 kg during pregnancy (Table 1). Only 1.9% of the women had a vaginal delivery; elective and nonelective cesarean deliveries accounted for 81.3% and 16.7% of deliveries, respectively. Compared to underweight/normal women, overweight/obese women had similar occurrences of preterm delivery (23.4% vs 22.7%, P = .871), significantly lower rates of low birthweight (14.2% vs 24.2%, P = .007) and nonelective cesarean deliveries (11.7% vs 18.3%, P = .042), and a significantly higher occurrence of fasting plasma glucose >92 mg/dL at 20–28 weeks (12.1% vs 6.6%, P = .027), hypertension during pregnancy (6.4% vs 2.7%, P = .019), and gestational age–adjusted birthweight >90th percentile (15.5% vs 5.0%, P < .001). Complications of delivery, major birth defects, and HIV transmission were similar between the 2 groups (7.3% vs 7.6%, P = .881; 2.6% vs 3.5%, P = .589; and 0.8% vs 0.5%, P = .661, respectively). An inadequate weight gain during pregnancy was associated with an increased risk of nonelective cesarean delivery (OR, 1.589 [95% CI, 1.077–2.346], P = .020). Excessive weight gain during pregnancy was not associated with either hypertension (OR, 1.364 [95% CI, .537–3.465], P = .514) or 20–28 week glucose level of >92 mg/dL (OR, 0.841 [95% CI, .399–1.772], P = .648), but was significantly associated with birthweight >90th percentile (OR, 2.271 [95% CI, 1.229–4.195], P = .009), and appeared to be protective against low birthweight (OR, 0.544 [95% CI, .323–.918], P = .023) and birthweight
- Published
- 2013
44. Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy
- Author
-
Floridia, M, Ravizza, M, Pinnetti, C, Tibaldi, C, Bucceri, A, Anzidei, G, Fiscon, M, Molinari, A, Martinelli, P, Dalzero, S, Tamburrini, E, Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy, Anceschi, Maurizio Marco, Massetti, Anna Paola, Mastroianni, Claudio Maria, Floridia M., Ravizza M., Pinnetti C., Tibaldi C., Bucceri A., Anzidei G., Fiscon M., Molinari A., Martinelli P., Dalzero S., Tamburrini E., Faldella G., Guerra B., Floridia, M., Ravizza, M., Pinnetti, C., Tibaldi, C., Bucceri, A., Anzidei, G., Fiscon, M., Molinari, A., Martinelli, Pasquale, Dalzero, S., Tamburrini, E., and Italian Group on Surveillance on Antiretroviral Treatment in, P. r. e. g. n. a. n. c. y.
- Subjects
antiretroviral treatment ,Adult ,medicine.medical_specialty ,Multivariate analysis ,Time Factors ,Pregnancy Trimester, Third ,HIV Infections ,Settore MED/17 - MALATTIE INFETTIVE ,Drug Administration Schedule ,Cohort Studies ,Young Adult ,Pregnancy ,Risk Factors ,Medicine ,Humans ,Pharmacology (medical) ,Young adult ,Pregnancy Complications, Infectious ,Univariate analysis ,treatment ,business.industry ,Obstetrics ,Confounding ,Infant, Newborn ,HIV ,Odds ratio ,Viral Load ,medicine.disease ,Infectious Disease Transmission, Vertical ,Surgery ,CD4 Lymphocyte Count ,Infectious Diseases ,Logistic Models ,Anti-Retroviral Agents ,Withholding Treatment ,HIV-1 ,RNA, Viral ,Female ,business ,Viral load ,Cohort study - Abstract
To investigate the risk factors for an HIV-1 RNA plasma viral load above 400 copies/mL in the third trimester of pregnancy.Data from a large national study were used. The possible determinants were assessed in univariate analyses and in a multivariate logistic regression model in order to adjust for possible confounders.Among 662 pregnancies followed between 2001 and 2008, 131 (19.8%) had an HIV-1 plasma copy number above 400/mL at the third trimester of pregnancy. In the multivariate analysis, the variables significantly associated with this occurrence were earlier calendar year (adjusted odds ratio [AOR] per additional calendar year, 0.70; 95% CI, 0.63-0.77; P.001), lower CD4 count at enrollment (AOR per 100 cells lower, 1.18; 95% CI, 1.09-1.27; P.001), HIV-1 RNA levels above 400 copies per mL at enrollment (AOR, 2.23; 95% CI, 1.50-3.33; P.001), and treatment modification during pregnancy (AOR, 1.66; 95% CI, 1.07-2.57; P=.024).Treatment changes in pregnancy significantly increase the risk of an incomplete viral suppression at the end of pregnancy. In HIV-infected women of childbearing age, proper preconception care, which includes the preferential prescription of regimens with the best safety profile in pregnancy, is likely to prevent an incomplete viral suppression at the end of pregnancy.
- Published
- 2011
45. Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study
- Author
-
Floridia, M., Ravizza, M., Masuelli, G., Giacomet, V., Martinelli, P., Degli Antoni, A., Spinillo, A., Fiscon, M., Francisci, D., Liuzzi, G., Pinnetti, C., Marconi, A. M., Tamburrini, E., Mori, F., Ortolani, P., dalle Nogare, E. R., Di Lorenzo, F., Sterrantino, G., Meli, M., Polemi, S., Nocentini, J., Baldini, M., Montorzi, G., Mazzetti, M., Rogasi, P., Borchi, B., Vichi, F., Del Pin, B., Pinter, E., Anzalone, E., Marocco, R., Mastroianni, C., Mercurio, V. S., Carocci, A., Grilli, E., Maccabruni, A., Zaramella, M., Mariani, B., Natalini Raponi, G., Guaraldi, Giovanni, Nardini, Giulia, Stentarelli, Chiara, Beghetto, Barbara, Degli Antoni, A. M., Molinari, A., Crisalli, M. P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Fabiano, V., Placido, G., Vivarelli, A., Castelli, P., Savalli, F., Portelli, V., Sabbatini, F., Bernini, L., Grossi, P., Rizzi, L., Alberico, S., Maso, G., Airoud, M., Soppelsa, G., Meloni, A., Dedoni, M., Cuboni, C., Ortu, F., Piano, P., Citernesi, A., Bordoni Vicini, I., Luzi, K., Roccio, M., Vimercati, A., Miccolis, A., Bassi, E., Guerra, B., Cervi, F., Puccetti, C., Murano, P., Contoli, M., Capretti, M. G., Marsico, C., Faldella, G., Sansone, M., Agangi, A., Tibaldi, C., Trentini, L., Todros, T., Frisina, V., Cetin, I., Brambilla, T., Savasi, V., Personeni, C., Giaquinto, C., Rinaldi, R., Rubino, E., Bucceri, A., Matrone, R., Scaravelli, G., Fundaro, C., Genovese, O., Cafforio, C., Tozzi, V., Massetti, P., Casadei, A. M., Cavaliere, A. F., Finelli, V., Cellini, M., Castelli Gattinara, G., Dalzero, S., Sacchi, V., De Pirro, A., Polizzi, C., Mattei, A., Pirillo, M. F., Amici, R., Galluzzo, C. M., Donnini, S., Baroncelli, S., Regazzi, M., Villani, P., Cusato, M., Cerioli, A., De Martino, M., Mastroiacovo, P., Moroni, M., Parazzini, F., Vella, S., Floridia, M, Ravizza, M, Masuelli, G, Giacomet, V, Martinelli, Pasquale, Degli Antoni, A, Spinillo, A, Fiscon, M, Francisci, D, Liuzzi, G, Pinnetti, C, Marconi, Am, Tamburrini, E, on behalf of The Italian Group on Surveillance on Antiretroviral Treatment in, Pregnancy, Floridia, M1, Italian Group on Surveillance on Antiretroviral Treatment in, P. r. e. g. n. a. n. c. y., Marco Floridia, Marina Ravizza, Giulia Masuelli, Vania Giacomet, Pasquale Martinelli, Anna Degli Antoni, Arsenio Spinillo, Marta Fiscon, Daniela Francisci, Giuseppina Liuzzi, Carmela Pinnetti, Anna Maria Marconi, Enrica Tamburrini, on behalf of The Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy [.., Capretti, M.G., Marsico, C., Faldella, G., and ].
- Subjects
Pyridines ,Pyridine ,HIV Infections ,Triglyceride ,Lopinavir ,Liver Function Tests ,Pregnancy ,HIV Infection ,Pharmacology (medical) ,Viral ,Pregnancy Complications, Infectious ,triglycerides ,pre-term delivery ,medicine.diagnostic_test ,Liver Function Test ,Obstetrics ,Medicine (all) ,Pregnancy Outcome ,Infectious ,virus diseases ,HIV ,pregnancy ,RNA ,Lipid ,Viral Load ,Lipids ,Infectious Diseases ,Tolerability ,Oligopeptide ,Population study ,RNA, Viral ,Female ,medicine.symptom ,bilirubin ,Viral load ,Oligopeptides ,Human ,medicine.drug ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,HIV RNA ,Anti-HIV Agents ,Atazanavir Sulfate ,Infectious Disease ,Bilirubin ,Cholesterol ,Pre-term delivery ,Triglycerides ,Pharmacology ,cholesterol ,Settore MED/17 - MALATTIE INFETTIVE ,medicine ,Humans ,business.industry ,Anti-HIV Agent ,medicine.disease ,Atazanavir ,CD4 Lymphocyte Count ,Pregnancy Complications ,Immunology ,Pregnancy Complications, Infectiou ,business ,Liver function tests ,Weight gain - Abstract
BACKGROUND: Atazanavir and lopinavir represent the main HIV protease inhibitors recommended in pregnancy, but comparative data in pregnant women are limited. METHODS: Women from a national observational study, exposed in pregnancy to either atazanavir or lopinavir, were compared for glucose and lipid profiles, liver function tests, CD4 count, HIV RNA and main pregnancy outcomes. Statistical methods included univariate and multivariable analyses. RESULTS: The study population included 428 pregnancies (lopinavir, 322; atazanavir, 106). The lopinavir group was characterized by higher rates of HIV diagnosis in pregnancy and treatment indication for maternal health, lower CD4 counts, higher HIV RNA levels, less frequent antiretroviral treatment at conception and shorter duration of drug exposure during pregnancy. No differences in pregnancy outcomes, glucose metabolism and weight gain were observed. The two groups also showed in a multivariable analysis similar odds for detectable HIV RNA in the third trimester (adjusted OR 0.85, 95% CI 0.35-2.10, P = 0.730). Total lipid levels were significantly higher in the lopinavir group (median values in the third trimester 239 versus 221 mg/dL for total cholesterol and 226 versus 181 mg/dL for triglycerides; P < 0.001 for both comparisons) and bilirubin levels were significantly higher in the atazanavir group (1.53 versus 0.46 mg/dL, P < 0.001). CONCLUSIONS: In this observational study atazanavir and lopinavir showed similar safety and activity in pregnancy, with no differences in the main pregnancy outcomes. Atazanavir use was associated with a better lipid profile and with higher bilirubin levels. Overall, the study findings confirm that these two HIV protease inhibitors represent equally valid alternative options.
- Published
- 2014
46. Pregnancy outcomes and cytomegalovirus DNAaemia in HIV-infected pregnant women with CMV
- Author
-
Floridia, M., primary, Pirillo, M.F., additional, Degli Antoni, A., additional, Molinari, A., additional, Tamburrini, E., additional, Pinnetti, C., additional, Guaraldi, G., additional, Nardini, G., additional, Masuelli, G., additional, Dalzero, S., additional, Cetin, I., additional, Sansone, M., additional, Amici, R., additional, Ravizza, M., additional, Mori, F., additional, Ortolani, P., additional, dalle Nogare, E.R., additional, Di Lorenzo, F., additional, Sterrantino, G., additional, Meli, M., additional, Polemi, S., additional, Nocentini, J., additional, Baldini, M., additional, Montorzi, G., additional, Mazzetti, M., additional, Rogasi, P., additional, Borchi, B., additional, Vichi, F., additional, Del Pin, B., additional, Pinter, E., additional, Anzalone, E., additional, Marocco, R., additional, Mastroianni, C., additional, Mercurio, V.S., additional, Carocci, A., additional, Grilli, E., additional, Maccabruni, A., additional, Zaramella, M., additional, Mariani, B., additional, Natalini Raponi, G., additional, Stentarelli, C., additional, Beghetto, B., additional, Degli Antoni, A.M., additional, Crisalli, M.P., additional, Donisi, A., additional, Piepoli, M., additional, Cerri, V., additional, Zuccotti, G., additional, Giacomet, V., additional, Coletto, S., additional, Di Nello, F., additional, Madia, C., additional, Placido, G., additional, Vivarelli, A., additional, Castelli, P., additional, Savalli, F., additional, Portelli, V., additional, Sabbatini, F., additional, Francisci, D., additional, Bernini, L., additional, Grossi, P., additional, Rizzi, L., additional, Alberico, S., additional, Maso, G., additional, Airoud, M., additional, Soppelsa, G., additional, Meloni, A., additional, Dedoni, M., additional, Cuboni, C., additional, Ortu, F., additional, Piano, P., additional, Citernesi, A., additional, Bordoni Vicini, I., additional, Luzi, K., additional, Spinillo, A., additional, Roccio, M., additional, Vimercati, A., additional, Miccolis, A., additional, De Gennaro, A., additional, Guerra, B., additional, Cervi, F., additional, Simonazzi, G., additional, Margarito, E., additional, Capretti, M.G., additional, Marsico, C., additional, Faldella, G., additional, Martinelli, P., additional, Agangi, A., additional, Capone, A., additional, Maruotti, G.M., additional, Tibaldi, C., additional, Trentini, L., additional, Todros, T., additional, Frisina, V., additional, Brambilla, T., additional, Savasi, V., additional, Personeni, C., additional, Giaquinto, C., additional, Fiscon, M., additional, Rubino, E., additional, Bucceri, A., additional, Matrone, R., additional, Scaravelli, G., additional, Genovese, O., additional, Cafforio, C., additional, Liuzzi, G., additional, Tozzi, V., additional, Massetti, P., additional, Casadei, A.M., additional, Cavaliere, A.F., additional, Cellini, M., additional, Castelli Gattinara, G., additional, Marconi, A.M., additional, Sacchi, V., additional, Ierardi, M., additional, Polizzi, C., additional, Mattei, A., additional, Galluzzo, C.M., additional, Donnini, S., additional, Baroncelli, S., additional, Floridia, M., additional, Villani, P., additional, Cusato, M., additional, Cerioli, A., additional, De Martino, M., additional, Mastroiacovo, P., additional, Parazzini, F., additional, and Vella, S., additional
- Published
- 2016
- Full Text
- View/download PDF
47. Pregnant with HIV before age 25: data from a large national study in Italy, 2001–2016
- Author
-
FLORIDIA, M., primary, MASUELLI, G., additional, TAMBURRINI, E., additional, CETIN, I., additional, LIUZZI, G., additional, MARTINELLI, P., additional, GUARALDI, G., additional, SPINILLO, A., additional, VIMERCATI, A., additional, MASO, G., additional, PINNETTI, C., additional, FRISINA, V., additional, DALZERO, S., additional, and RAVIZZA, M., additional
- Published
- 2017
- Full Text
- View/download PDF
48. Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapy
- Author
-
Giuliano, M., primary, Pirillo, M.F., additional, Liotta, G., additional, Andreotti, M., additional, Floridia, M., additional, Ciccacci, F., additional, Jere, H., additional, Sagno, J.-B., additional, Amici, R., additional, Mancinelli, S., additional, Marazzi, M.C., additional, Vella, S., additional, and Palombi, L., additional
- Published
- 2017
- Full Text
- View/download PDF
49. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011
- Author
-
Floridia, M., Mastroiacovo, P., Tamburrini, E., Tibaldi, C., Todros, T., Crepaldi, A., Sansone, M., Fiscon, M., Liuzzi, G., Guerra, B., Vimercati, A., Vichi, F., Vicini, I., Pinnetti, C., Marconi, A. M., Ravizza, M., Mori, F., Ortolani, P., dalle Nogare, E. R., Di Lorenzo, F., Sterrantino, G., Meli, M., Polemi, S., Nocentini, J., Baldini, M., Montorzi, G., Mazzetti, M., Rogasi, P., Borchi, B., Pinter, E., Anzalone, E., Marocco, R., Mastroianni, C., Mercurio, V. S., Carocci, A., Grilli, E., Maccabruni, A., Zaramella, M., Mariani, B., Natalini Raponi, G., Guaraldi, G., Luzi, K., Nardini, G., Stentarelli, C., Degli Antoni, A. M., Molinari, A., Crisalli, M. P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Fabiano, V., Coletto, S., Placido, G., Vivarelli, A., Castelli, P., Savalli, F., Portelli, V., Sabbatini, F., Francisci, D., Bernini, L., Alberico, S., Maso, G., Tropea, M., Meloni, A., Dedoni, M., Cuboni, C., Ortu, F., Piano, P., Citernesi, A., Spinillo, A., Roccio, M., Miccolis, A., Bassi, E., Cervi, F., Puccetti, C., Murano, P., Contoli, M., Capretti, M. G., Marsico, C., Faldella, G., Martinelli, P., Agangi, A., Trentini, L., Masuelli, G., Garetto, S., Cetin, I., Brambilla, T., Savasi, V., Giaquinto, C., Rinaldi, R., Rubino, E., Bucceri, A., Matrone, R., Scaravelli, G., Fundaro, C., Genovese, O., Cafforio, C., Tozzi, V., Massetti, P., Anceschi, M., Casadei, A. M., Cavaliere, A. F., Finelli, V., Cellini, M., Castelli Gattinara, G., Dalzero, S., Sacchi, V., De Pirro, A., Polizzi, C., Mattei, A., Pirillo, M. F., Amici, R., Galluzzo, C. M., Donnini, S., Baroncelli, S., Regazzi, M., Villani, P., Cusato, M., Cerioli, A., De Martino, M., Moroni, M., Parazzini, F., Vella, S., Floridia, M, Mastroiacovo, P, Tamburrini, E, Tibaldi, C, Todros, T, Crepaldi, A, Sansone, M, Fiscon, M, Liuzzi, G, Guerra, B, Vimercati, A, Vichi, F, Vicini, I, Pinnetti, C, Marconi, A, Ravizza, M, Martinelli, Pasquale, and The Italian Group on Surveillance on Antiretroviral Treatment in, Pregnancy
- Subjects
Male ,HIV Infections ,transcriptase inhibitors ,Cohort Studies ,chemistry.chemical_compound ,Pregnancy ,Prevalence ,Birth Weight ,Young adult ,Pregnancy Complications, Infectious ,education.field_of_study ,Obstetrics ,Coinfection ,Antiretroviral therapy ,birth defects ,efavirenz ,HIV ,non-nucleoside reverse transcriptase inhibitors ,nucleoside reverse transcriptase inhibitors ,pregnancy ,protease inhibitors ,women ,Obstetrics and Gynecology ,Abnormalities, Drug-Induced ,Middle Aged ,Italy ,Maternal Exposure ,Reverse Transcriptase Inhibitors ,Female ,Cohort study ,Adult ,medicine.medical_specialty ,Efavirenz ,Adolescent ,Anti-HIV Agents ,Birth weight ,Population ,Antiretroviral Therapy ,Birth defects ,HIV-1 ,Young Adult ,Hepatitis B, Chronic ,medicine ,Humans ,education ,business.industry ,Infant, Newborn ,Odds ratio ,Hepatitis C, Chronic ,medicine.disease ,Infectious Disease Transmission, Vertical ,Surgery ,Pregnancy Trimester, First ,chemistry ,business - Abstract
Objective We used data from a national study of pregnant women with HIV to evaluate the prevalence of congenital abnormalities in newborns from women with HIV infection. Design Observational study. Setting University and hospital clinics. Population Pregnant women with HIV exposed to antiretroviral treatment at any time during pregnancy. Methods The total prevalence of birth defects was assessed on live births, stillbirths, and elective terminations for fetal anomaly. The associations between potentially predictive variables and the occurrence of birth defects were expressed as odds ratios (ORs) with 95% confidence intervals (95% CIs) for exposed versus unexposed cases, calculated in univariate and multivariate logistic regression analyses. Main outcome measures Birth defects, defined according to the Antiretroviral Pregnancy Registry criteria. Results A total of 1257 pregnancies with exposure at any time to antiretroviral therapy were evaluated. Forty-two cases with major defects were observed. The total prevalence was 3.2% (95% CI 1.9–4.5) for exposure to any antiretroviral drug during the first trimester (23 cases with defects) and 3.4% (95% CI 1.9–4.9) for no antiretroviral exposure during the first trimester (19 cases). No associations were found between major birth defects and first-trimester exposure to any antiretroviral treatment (OR 0.94, 95% CI 0.51–1.75), main drug classes (nucleoside reverse transcriptase inhibitors, OR 0.95, 95% CI 0.51–1.76; non-nucleoside reverse transcriptase inhibitors, OR 1.20, 95% CI 0.56–2.55; protease inhibitors, OR 0.92, 95% CI 0.43–1.95), and individual drugs, including efavirenz (prevalence for efavirenz, 2.5%). Conclusions This study adds further support to the assumption that first-trimester exposure to antiretroviral treatment does not increase the risk of congenital abnormalities.
- Published
- 2013
50. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011
- Author
-
Antinori, A, Marcotullio, S, Ammassari, A, Andreoni, M, Angarano, G, Armignacco, O, Carosi, G, Cinque, P, d'Arminio Monforte, A, Di Perri, G, Ensoli, B, Floridia, M, Galli, M, Mastroianni, C, Matteelli, A, Mazzotta, F, Moroni, M, Pal, G, Puoti, M, Puro, V, Rizzardini, G, Sagnelli, E, Vella, S, Vullo, V, Lazzarin, A, Italian HIV Guidelines Working Group, Baldelli, Franco, Antinori, A, Marcotullio, S, Ammassari, A, Andreoni, M, Angarano, G, Armignacco, O, Carosi, G, Cinque, P, d'Arminio Monforte, A, Di Perri, G, Ensoli, B, Floridia, M, Galli, M, Mastroianni, C, Matteelli, A, Mazzotta, F, Moroni, M, Pal, G, Puoti, M, Puro, V, Rizzardini, G, Sagnelli, E, Vella, S, Vullo, V, Lazzarin, A, and Gori, A
- Subjects
Anti-HIV Agents ,MATERNAL-INFANT TRANSMISSION ,RAPID SCREENING-TEST ,hiv ,HIV Infections ,HIV-INFECTED PATIENTS ,INTIMA-MEDIA THICKNESS ,RANDOMIZED COMPARATIVE TRIAL ,QUALITY-OF-LIFE ,Humans ,HIV Infection ,infected persons ,antiretrovirals ,REVERSE-TRANSCRIPTASE INHIBITORS ,SOCIETY EACS GUIDELINES ,CENTRAL-NERVOUS-SYSTEM ,Anti-HIV Agent ,PNEUMOCYSTIS-CARINII-PNEUMONIA ,IMMUNODEFICIENCY-VIRUS TYPE-1 ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,Italy ,HIV-1 ,NON-HODGKIN-LYMPHOMA ,Human - Abstract
Authorized by the Ministry of Health and Istituto Superiore di Sanità, National AIDS Centre. In collaboration with the National AIDS Commission and the Conference of Associations for the War Against AIDS, Ministry of Health, and with the Italian Society of Infectious and Tropical Diseases (SIMIT).
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.